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ABSTRACT 
The highly prostate specific serine protease kallikrein-related peptidase 3 (KLK3, 
also known as prostate specific antigen, PSA) is widely used as a biomarker for 
prostate cancer and it has also been postulated that it may play a part in tumour 
growth. Especially interestesting is the antiangiogenic effect exerted by 
proteolytically active KLK3 in cell line models. In order to stimulate the proteolytic 
activity of KLK3, a series of peptides have been developed by phage display 
methodology. Even though the peptides are quite potent KLK3 stimulators, they are 
not directly suitable for in vivo studies or use as drugs. 
Even though there are many natural and unnatural biologically active peptides, 
they suffer from rapid clearance via the liver and kidneys and proteolytic 
degradation of the compounds both in the gastrointestinal tract and other parts of the 
body. This gives peptides a poor oral bioavailability meaning that they are usually 
administered as intravenous or intramuscular injections. Several different strategies 
have been developed in order to access compounds with improved bioavailability 
including modifications of the peptide structure, development of pseudopeptides and 
development of small molecular weight peptidomimetics.  
This thesis concentrates on the further development of the two most potent 
peptides known to stimulate KLK3, i.e. B-2 and C-4. The main part of the work was 
concentrated on the replacement of disulphide bridges in the peptides in order to 
both gain more information on which residues are necessary for obtaining the 
biological activity and at the same time also gain information on how changes to the 
geometry of the disulphide bridge affects the activity. 
A series of different disulphide bridge mimicking building blocks were designed 
and synthesised with the intention of using them in a protocol for solid-phase 
synthesis of KLK3 stimulating peptides. Unfortunately, the use of these building 
blocks in the synthesis of pseudopeptides based on C-4 turned out to be an 
unsurmountable challenge and the synthesis had to be completed using a different 
strategy in which the key step was the use of ring-closing metathesis (RCM) for the 
cyclisation of the partly completed pseudopeptide. Pleasingly, the synthesis of 
pseudopeptide analogues of the B-2 peptide using the building blocks was more 
successful. In total three pseudopeptide analogues of C-4 and four of B-2 were 
synthesised and shown to retain the biological activity of the parent peptides. 
Based on the information from the synthesised pseudopeptides and a molecular 
modelling study, a 4-quinolone based peptidomimetic was designed to mimic the C-
4 peptide and a synthetic protocol was devised to access this compound. Even 
though the synthesis of the desired target compound has so far not been successful, 
the synthetic protocol that was designed has given access to a number of 1,2,8-
trisubstituted 4-quinolone derivatives. 
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1 GENERAL INTRODUCTION 
1.1 HUMAN KALLIKREIN-RELATED PEPTIDASE 3 AND 
ITS ROLE IN PROSTATE CANCER 
Human kallikrein-related peptidase 3 (KLK3 or hK3), that is better known as 
prostate-specific antigen or PSA, is a 28 kDa, 237 residue protein belonging to the 
family of 15 peptidases referred to as kallikreins.
1,2
 It is found almost exclusively in 
the epithelium of the prostate although small amounts have also been isolated from 
for example the ileum, testis and thyroid gland.
3,4
 KLK3 exhibits chymotrypsin-like 
serine protease activity with a preference for cleavage of substrates after tyrosine, 
leucine or glutamine residues.
5-8
 Its main physiological role is cleavage of the gel-
forming proteins semenogelin I and II in order to dissolve seminal clots and thus 
improve sperm motility.
5-7
 The active site of the members of the kallikrein family 
comprises the catalytic triad consisting of residues His57, Asp102 and Ser195.
9-12
 In 
the so-called classical kallikreins (KLKs 1-3), the active site is located under a large, 
flexible insertion consisting of 11 amino acid residues following Asn95 (KLK1) or 
Asp95 (KLKs 2 and 3). This insertion is referred to as the kallikrein loop (coloured 
yellow in Figure 1) and has been suggested to play a role in the activity of KLKs 1-
3.
10,12-15
 The biosynthesis of KLK3 occurs mainly in the epithelium of healthy 
prostate and is decreased by abnormalities in the prostate although it is not 
completely eliminated. Both malignant (e.g. prostate cancer) and non-malignant (e.g. 
benign prostatic hyperplasia, BPH) conditions cause modifications to the structure of 
the prostatic tissue resulting in leakage of KLK3 into the plasma.
16
 Once in the 
plasma, KLK3 is deactivated by protease inhibitors such as α1-antichymotrypsin 
(ACT) and α2-macroglobulin that form covalent complexes with KLK3 thus 
inhibiting its activity.
17,18
 Various other inactive forms of KLK3 such as pro-KLK3 
and nicked KLK3 have also been found in plasma.
19
 
It has been shown that malign or benign changes in the prostate cause leakage of 
KLK3 into the plasma. This can be utilised for detecting and monitoring the risk for 
an individual to develop prostate cancer. This is especially helpful as prostate cancer 
does not cause clinical symptoms until it has spread into surrounding tissues and 
started affecting the urinary function or it has metastasised into other tissues, mainly 
the lymph nodes or bones. This is further complicated by the fact that prostate cancer 
can exhibit a number of different clinical behaviours, ranging from insignificant, 
slow-growing tumours to aggressively metastatic and fatal forms.
20-22
 Taking this 
into account, screening individuals believed to be at higher risk of developing 
prostate cancer is helpful. The diagnosis can then be verified by using, in addition to 
the KLK3 assay, a digital rectal examination, transrectal ultrasonography and/or 
transrectal ultra-sound guided biopsies.
23
 
Prostate cancer is the second most common form of cancer in males worldwide 
(the most common in the developed world) and sixth in the number of cancer deaths 
worldwide, although there are large variations in the incidence rates.
24
 When 
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examining the situation in the United States, it has been shown that around one in six 
men will develop prostate cancer in their lifetime with the mortality rate being 3.4 
%.
25
 
   
Figure 1 The structure of KLK3 with the kallikrein loop highlighted in yellow. The right-hand 
image shows a close-up of the position of the active site under the kallikrein loop. 
Images adapted from ref 11. 
Even though the KLK3 assay is widely used in screening for prostate cancer and has 
proven highly effective, it does also have some drawbacks. One known problem is 
that many benign conditions (BPH, prostatitis) also cause elevations in the serum 
levels of KLK3 which this simple test cannot discriminate from malign conditions. 
This combined with the variations in the growth rates of tumours causes an 
overdiagnosis of prostate cancer which in turn causes many patients to have to go 
through unnecessary treatments such as prostatectomies or radiotherapy. Thus the 
patients have to suffer the side-effects of these treatments when only having a benign 
or latent condition.
19
 In addition to the problems associated with distinguishing 
clinically relevant tumours from others it has also been suggested that measuring 
KLK3 levels will only reflect on the relative risk of cancer. Additionally, no level 
can be defined that would completely rule out the possibility of cancer.
26
 From this, 
it can be concluded that other biomarkers are also required for the screening of 
prostate cancer. Other possible biomarkers that have been suggested include human 
kallikrein-related peptidase 2 (KLK2), early prostate cancer antigen (EPCA), 
prostate cancer antigen 3 (PCA3) and/or hepsin.
27,28
 Although a combination of the 
serum level of KLK2 with measurements of different forms of KLK3 have been 
claimed to improve the diagnosis and prognosis of prostate cancer,
19,29-31
 the search 
for new biomarkers still continues.
27,32
 
Even though the role of KLK3 in prostate cancer is still largely unknown, it has 
been shown that it inhibits angiogenesis. In both in vivo and in vitro models KLK3 
has been proven to reduce the growth of blood vessels by inhibiting endothelial cell 
growth, invasion and migration.
33,34
 In a HUVEC (human umbilical-vein endothelial 
cells) model it has been shown that KLK3 can inhibit tube formation, indicating that 
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the enzymatic activity of KLK3 is important for the antiangiogenic effects
35
 and that 
peptides can be used to enhance this activity.
36
 It has also been shown that poorly 
differentiated tumours show a lower level of KLK3 expression.
37-39
 
On the other hand, several investigations have also shown that KLK3 may have a 
role in promoting tumour growth and the formation of metastases. For example, 
KLK3 has been postulated to promote osteoblast proliferation and thereby play a 
role in the formation of bone metastases.
40,41
 A recent study has also shown that the 
lowering of KLK3 levels in an LNCaP human prostate cancer cell line reduced the 
growth rates of these cells. This would suggest that enzymatically active KLK3 is 
required for the progression of prostate cancer.
42
 
1.2 COMPOUNDS MODULATING THE ENZYMATIC 
ACTIVITY OF KLK3 
KLK3 and especially its enzymatic activity seems to play an important part in the 
development of prostate cancer. As KLK3 has been shown to both inhibit
35,39
 and 
stimulate prostate tumour growth as well as promoting both the formation of bone 
metastases
43,44
 in prostate cancer and stimulating tumour growth in breast cancer,
45,46
 
compounds both inhibiting and stimulating KLK3 have been investigated. It has 
been shown that metal ions such as Zn
2+
, Hg
2+
, and, to a lesser extent, Mn
2+
 inhibit 
the hydrolysis of the seminal plasma motility inhibitor precursor/semenogelin I 
(SPMIP/SgI) by KLK3 and chymotrypsin.
7
 As KLK3 exhibits proteolytic activity 
similar to other serine proteases, several inhibitors of KLK3 have been found. 
Adlington et al. have used a β-lactam derivative known to inhibit other serine 
proteases to develop several compounds inhibiting KLK3, the most potent (1) had an 
IC50-value of 226 nM.
47,48
 The β-lactams have also been used to study the 
mechanism for KLK3 inhibition.
49
 A more recent screening of a library of 
approximately 50 000 compounds identified two other compounds that inhibit KLK3 
at micromolar concentrations and also exhibit selectivity for KLK3 over 
chymotrypsin, 2 was the most potent of these with an IC50-value of 300 nM.
35
 Based 
on studies of peptide substrates for KLK3,
50
 several peptidyl boronic acids such as 3 
that inhibit KLK3 have also been developed and utilised to further elucidate the 
mechanism of inhibition.
51,52 
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As proteolytically active KLK3 has also been hypothesised to inhibit tumour growth, 
compounds stimulating this activity could aid in the treatment of prostate cancer. Wu 
et al. used phage-display methodology to identify three peptides that bind 
specifically to KLK3 and exhibit a significant stimulating effect. The cyclic peptides 
denoted A-1, B-2 and C-4 are shown in Figure 2.
53
 The most potent of these was the 
bicyclic peptide C-4 (4). It has been suggested that these peptides bind in the vicinity 
of the active site of KLK3.
10,53,54
 Additionally, the binding affinity of the peptides 
was increased by Zn
2+
 which is known to inhibit KLK3.
53
 Some short, linear 
peptides that approximately double the proteolytic activity of KLK3 have also been 
developed by another group but this line has not been explored further.
14
 
Synthetically modified analogues of peptides C-4 (4) and B-2 (5) have also been 
demonstrated to retain their biological activity.
54,55
 Replacement studies performed 
on these peptides have also given some indications of which residues in the peptides 
are important for retaining the biological activity. In the B-2 peptide all residues 
appear to be important for retaining the biological activity while in the C-4 peptide, 
several of the residues can be replaced with alanine without a significant loss in 
biological activity.
54-56
 It has also been shown that the stability of peptide B-2 in 
plasma can be increased without losing the biological activity by replacing the 
terminal disulphide bridge by a bridge consisting of γ-aminobutyric acid and aspartic 
acid.
55 
 
Figure 2 KLK3 stimulating peptides identified by phage display.53 
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For development of peptide mimicking compounds, it would be important to know 
the binding site of the peptides on the target enzyme. This information is often 
derived from the crystal structure of the protein in question. In the case of KLK3 this 
work is quite complicated as the only structural information available are two crystal 
structures found in the Protein Data Bank (PDB) (2ZCK and 3QUM), unfortunately 
both of these structures also include an antibody. The 2ZCK-structure also contains a 
substrate molecule which leads to some uncertainty if the crystal structure actually 
corresponds to the proteolytically active form of the enzyme or not.
11,12
 Even though 
there is some conformational data available on the peptides that stimulate KLK3, the 
inherent flexibility of peptides adds an additional level of complexity to this work as 
it is difficult to determine whether the conformations observed in solution are 
actually the biologically active ones.
54
  
Another interesting alternative to the crystal structures can be found in a recently 
published modelling study on KLK3.
10
 In this study, a homology model of KLK3 
was constructed based on the structural information available on other members of 
the kallikrein family, especially KLKs 1-3 that share the flexible kallikrein loop that 
covers the active site of the enzyme. Based on the structural information, a 
pharmacophore model was constructed. This model was used for virtual screening of 
compound libraries which identified a few compounds with a weak stimulating 
effect on KLK3, thereby at least in part verifying the correctness of the model.
10
 Of 
the compounds presented in the study, 7 was the most active, increasing the 
proteolytic activity of KLK3 by 7 %. The small molecular weight compounds are 
suggested to bind on the kallikrein loop, in the same place as peptides 4-6 that have 
been discussed previously. 
 
 
1.3 PEPTIDES AND THEIR ROLE IN DRUG DISCOVERY 
1.3.1 NATURAL PEPTIDES 
A peptide can be seen as a polymeric chain consisting of a number of amino acid 
residues connected via amide bonds which in peptides are referred to as peptide 
bonds, the structure of a peptide bond is shown in Figure 3. A peptide containing two 
amino acid residues is called a dipeptide, three residues make a tripeptide, etc. A 
chain of up to 50 amino acid residues is denoted an oligopeptide, 50-100 residues a 
polypeptide and any chain longer than this would be referred to as a protein. These 
definitions are, however, somewhat arbitrary and additional definitions such as small 
proteins are also used in shorter peptide chains. 
General introduction 
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All peptides and proteins found in humans consist of a set of 20 amino acids 
collectively called the proteinogenic amino acids. In recent years selenocysteine 
(Sec, U) and pyrrolysine (Pyl, O) have also been added to this list as it has been 
found that they are also genetically encoded in the biosynthesis of peptides.
57
 The 
common feature for all of the amino acids except glycine is the side chain attached to 
the stereogenic α-carbon. The amino acids found in endogenous peptides and 
proteins are predominantly in the L-configuration although some examples of 
peptides incorporating D-amino amino acids can be found in archaea and some 
bacteria. 
 
Figure 3 General structure of the backbone of a peptide chain 
Another structural trait of peptides and proteins are the disulphide bridges. These 
bridges are formed when a covalent bond is formed between the sulphurs of two 
cysteine residues, forming what is often referred to as a cystine unit. The disulphide 
bridges are important for the correct folding and stability of proteins and peptides, 
either by cross-linking different parts of one peptide chain (as in ribonuclease A
58
) or 
by connecting separate peptide chains (as in insulin
59,60
). This stabilisation is 
especially important in proteins that are excreted into the extracellular medium
61
 as 
most cell compartments are reducing environments that will degrade disulphide 
linkages rapidly unless a sulfhydryl oxidase is present.
62
 Disulphide bridges are 
characterised by the cis-like geometry of the -S-S- bond and the dihedral angle along 
said bond which is close to ±90° (χ3, Figure 4).
63,64
 
 
Figure 4 The structure of a disulphide bridge and its dihedral angles.64 
As the chain length of the peptide grows the number of intramolecular interactions 
increases and gives rise to a number of secondary structures such as turns, helices 
and sheets within the peptide structure. In shorter peptides the most prevalent 
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secondary structure is the β-turn, whereas e.g. in proteins the different secondary 
structures play important roles in determining the overall 3D-structure of the protein. 
Because of the large diversity of the side-chains of the amino acids present in 
peptides or proteins they can interact with their targets in a number of different ways. 
These interactions include electrostatic/polar interactions such as ionic or hydrogen 
bonding, π-π-interactions, and van der Waals interactions. 
Peptides have many different biological activities. In humans a number of 
bioactive peptides function as e.g. neurotransmitters or hormones. Examples of 
peptide neurotransmitters are orexin,
65
 somatostatin,
66
 substance P
67
 and the family 
of opioid peptides (e.g. endorphin).
68
 Representative examples of peptide hormones 
are prolactin,
69
 vasopressin
70
 and oxytocin.
71
 
Many toxins found in venomous snakes and other animals also contain active 
peptide components. Examples of these peptides include the neurotoxic conotoxins 
from marine cone snails,
72
 melittin and apamine from bee venom that have also 
found use in cancer therapy
73
 and the nicotinic receptor antagonist cobratoxin that 
can be found in the venom of some species of cobra.
74
 
Peptides also have other biological effects such as flavour compounds. Examples 
of this are the artificial sweetener aspartame
75
 and the so-called beefy meaty peptide 
that is responsible for the taste of meat.
76
 
1.3.2 SYNTHETIC PEPTIDES 
The field of peptide chemistry is generally considered to have started in the early 
20
th 
with the work of Emil Fischer beginning with the synthesis of the dipeptide 
glycylglycine (Gly-Gly) from 3,5-diketopiperazine in 1901.
77,78
 Further 
developments toward modern peptide synthesis were e.g. Curtius’ development of 
acyl azides for activating amines for the formation of peptide bonds in 1902,
79
 
Fischers first synthesis of the octadecapeptide Leu-Gly3-Leu-Gly3-Leu-Gly9 in 
1907,
80
 Bergmann and Zervas’ development of the concept of removable protecting 
groups in 1932
81
 and du Vigneauds work on characterising and synthesising the 
biologically active peptide oxytocin in the 1950s.
82,83
 
The key step in the synthesis of peptides is the formation of the amide bond; this 
is usually done by activation of the carboxylic acid moiety before its reaction with an 
amine. The first of these activating agents were the carbodiimides.
84,85
 Using this 
methodology carries with it the limitation that it may form an aromatic, cyclic 
intermediate that can lead to racemisation of the amino acid,
86,87
 although this 
problem can be minimised by using an additive such as HOBt
87,88
 or HOAt.
89
 
†
 The 
later developments of coupling reagents are usually referred to as onium salts which 
                                                 
† HOBt = 1-Hydroxybenzotriazole; HOAt = 1-Hydroxy-7-azabenzotriazole; HATU = 1-
[Bis(dimethylamino-)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate; 
HBTU = N,N,N′,N′-Tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate; TBTU = O-
(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate; BOP = (Benzotriazol-1-
yloxy)tris(dimethylamino)phosphonium hexafluorophosphate; PyBOP = (Benzotriazol-1-
yloxy)tripyrrolidinophosphonium hexafluorophosphate; HMPA = hexamethylphosphoramide 
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are used in the presence of a base, typically diisopropylethylamine (DIPEA). 
Representative examples from the group of ammonium/uronium reagents are 
HATU,
90
 HBTU
90,91
 and the corresponding tetrafluoroborate salt of the latter, 
TBTU.
92-95
 The group of phosphonium reagents can be exemplified by BOP
96
 which 
was later developed into PyBOP
97
 in order to avoid the formation of carcinogenic 
HMPA as a by-product. 
The advent of modern peptide chemistry has also required the development of a 
number of different protecting groups that can be selectively manipulated. These 
protecting groups can be split into three different classes: acid labile, base labile and 
those cleaved by other methods. The amine protecting benzyloxycarbonyl group 
(Cbz or Z), which was the first one published, falls into the last of these classes as it 
is removed by catalytic hydrogenation.
81,98
 Other example of this class are the allyl 
ester used to protect acids and allyloxycarbonyl (Alloc-) used for amines,
99
 which 
can both be cleaved with a Pd(0)-reagent, e.g. Pd(PPh3)4
99
. Some typical examples of 
acid labile protecting groups are the tert-butyl ester for protection of acids
100
 and the 
tert-butoxycarbonyl (Boc-)
101,102
 and trityl groups (Tr-)
103-105
 for the protection of 
amines. If a protecting group removable by base is required, the options include the 
fluorenylmethoxycarbonyl (Fmoc-)
106
 and methyl/ethyl esters
107-109
 for amines and 
acids, respectively. In addition to the examples given here there are a large number 
of other possibilities that can be used depending on the requirements of the specific 
applications.
98,110,111
 
Until the early 1960s peptide synthesis was performed in solution phase which 
involved tedious purification and identification between every step of the synthesis. 
The whole field of peptide chemistry was revolutionised in 1963 when Robert 
Merrifield published his paper on solid phase peptide synthesis (SPPS).
112
 Since this 
original publication numerous developments have been made to the original solid 
phase resin in order to improve it for specific applications. In SPPS typical resins 
used are the acid-labile Rink and Wang resins. One modification of these worth 
noting is the Rink amide resin, which upon acidic cleavage of the peptide results in a 
product with a C-terminal amide instead of a free carboxylic acid. One of the most 
important developments of SPPS was the advent of systems that enabled the 
automated synthesis of peptides which significantly reduced the number of man-
hours needed for the synthesis of longer peptides.
113,114
 
The strategy for SPPS can be briefly summarised as in Figure 5: the C-terminal 
residue of the target peptide is attached to the resin and its N-terminal protection is 
removed, the following N-protected residue is coupled and its N-terminal protection 
is removed (the resin is washed between each separate step). This process is then 
repeated until the desired peptide sequence is complete and finally cleaved from the 
resin using a suitable, often acidic, solution with additives to prevent side 
reactions.
115-118
 The final peptide can then be isolated by precipitation, followed by 
purification by preparative HPLC. 
In the past decades a new direction in peptide synthesis has emerged, i.e. heating 
by microwave irradiation to speed up the synthesis.
93,119
 By heating the reaction 
mixture to a temperature of 60 °C during the coupling step it has been possible to  
 9 
 
Figure 5 The general principle of SPPS. X: Temporary Nα-protecting group. Y: Semi-
permanent side chain amino acid (Aaa) protecting groups. R: C-terminal 
functionality, typically OH or NH2. Image reproduced from reference 93 with 
permission of The Royal Society of Chemistry. 
shorten the reaction time required from 45 min to 5 min. The reason for this is still 
under debate, some sources suggest a so-called microwave effect that stretches the 
peptide out during the reaction thus facilitating the reaction.
120,121
 Even though 
microwave heating can be useful in peptide synthesis care must be taken in some 
couplings, for example the amino acids histidine and cysteine have been shown to 
racemise when coupled under microwave irradiation.
93,120
 Microwave heating has 
also later been utilised in automated peptide synthesis.
122,123
 
1.3.3 PEPTIDES AS DRUGS 
Even though many biologically active peptides have been isolated from natural 
sources, the number of peptides or derivatives thereof that are currently in use as 
drugs or other applications is relatively low.
124,125
 
At present there are a number of natural or modified peptides in therapeutic use; 
e.g. insulin (treatment of diabetes), leuprorelin (treatment of hormone-responsive 
cancers), bivalirudin (anticoagulant, direct thrombin inhibitor), cyclosporine 
(immunosuppressant), calcitonin (osteoporosis and hypercalcemia) and enfuvitide 
(antiretroviral for the treatment of HIV-1 infections), to name a few. In addition to 
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these a number of synthetic peptides are also in use; for example eptifibatide 
(inhibits platelet aggregation), atosiban (prevents premature labour), octreotide (used 
in the treatment of acromegaly and gigantism) and desmopressin (treatment of 
diabetes insipidus, bedwetting, or nocturia).
125
 
As peptides and proteins are abundant in nature and an essential part of the 
nutrition for humans, a number of different routes and methods for the metabolism 
and elimination of these types of compounds exist that significantly lower their 
utility as pharmaceutical compounds. When orally administered peptides and 
proteins reach the gastrointestinal (GI) tract, they are immediately degraded by 
pepsin, an endopeptidase excreted from the gastric mucosa. The oligopeptides 
resulting from this degradation then exit into the small intestine where they are 
further degraded by a number of endo- and exopeptidases resulting in single amino 
acids and di- or tripeptides.
117,126,127
 This rapid degradation inevitably leads to a low 
level of oral bioavailability for peptides, it has been estimated to be only 1-2 %.
128
 
Using a parenteral route for the administration of peptides can overcome part of 
the problems even though these peptides are also eliminated relatively quickly. 
Small peptides entering the circulation are typically metabolised within a few 
minutes by the peptidases in the plasma and larger peptides are eliminated by the 
kidneys or liver.
126,127,129
 Once the peptide or protein has been eliminated from the 
blood stream it is also rapidly metabolised. It seems that smaller peptides are 
generally eliminated in the kidneys and larger peptides and proteins in the liver. This 
is, however, also affected by other factors such as hydrophobicity and overall charge 
of the compound.
126,129
 For larger compounds other factors such as aggregation or 
denaturation also cause pharmaceutical compounds to lose their biological 
activity.
127,129,130
 
In addition to the problems associated with metabolism and elimination many 
peptide or protein based therapeutics also exhibit physicochemical properties that are 
unfavourable for use as pharmaceutical compounds. The molecular weight and size 
of this type of compounds means that in most cases passive diffusion over cell 
membranes is not possible and hence a mechanism for active transport would be 
needed. These problems are further increased by the hydrophilicity of most peptides 
and proteins. As most membranes are hydrophobic, this further limits passive 
transport through membranes, including the blood-brain-barrier.
127
 
At least some of these limitations can be overcome by administering the peptide 
as a subcutaneous or intravenous injection, in the case of desmopressin and oxytocin 
the use of a nasal spray has also been shown to be an effective way of administering 
the drug. In addition to the discomfort an injection can cause the patient, the rapid 
clearance of the peptides also means that repeated injections are required causing 
fluctuations in the plasma concentration of the drug.
127
 Linear peptides also carry 
with them the additional problem that they are conformationally flexible. This 
flexibility can cause a lack of specificity (non-selective binding to additional targets 
or receptors), side effects and immunogenic responses.
131,132
 
The final and possibly biggest limitation to the use of peptides for therapeutic 
applications is cost or complexity of production of large quantities of the active 
compound. Even though there are many ways for producing peptides including 
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chemical synthesis, recombinant DNA technology, transgenic plants and animals and 
enzymatic synthesis all of these methods carry with them limitations. Chemical 
synthesis offers virtually unlimited possibilities for the modification of peptides but 
only produces small amounts of the product, the large number of synthetic steps 
required for large peptides also severely limits the overall yield. The 
biotechnological methods can generally be used to produce larger amounts but offer 
limited possibilities for modifications of the natural product.
124
 An exception to these 
statements is the natural peptides and peptide derivatives used as drugs, e.g. insulin 
can be produced cheaply in large quantities by using biological methods.
133
  
With all this being said, peptides still offer many advantages that make them 
attractive compounds in drug-discovery projects. As the peptides used for 
modulating the activity of some drug targets exploit the efficacy of a natural protein 
while comprising only a small part of the structure they often exhibit a higher 
selectivity and efficacy than small molecular compounds.
131,134
 As peptides are 
constructed from amino acids, the risk of toxic metabolites is also significantly lower 
than for small molecules. Given both the type and short half-life of the metabolites 
there is also a low risk of accumulation in the tissues.
131,132
 
1.4 MODIFIED PEPTIDES, PSEUDOPEPTIDES AND 
PEPTIDOMIMETICS 
Due to the problems with using peptides as drugs outlined in Chapter 1.3.3 
considerable effort is currently being put into developing peptides into compounds 
with improved pharmacokinetic properties. Depending on the extent of the 
modification the resulting product can be referred to as a modified peptide, a 
pseudopeptide or a peptidomimetic. The differences between these alternatives will 
be discussed in this chapter using selected examples. More information can be found 
in any of several more comprehensive reviews that have been written on the 
subject.
135-137
 
1.4.1 MODIFIED PEPTIDES AND PSEUDOPEPTIDES 
The simplest modification of a peptide is to replace one or more of the original 
amino acid residues with a different natural or unnatural amino acid. One application 
for this is the use of an alanine scan to determine which residues are important for 
achieving the biological effect of the peptide or protein. When working with a small 
peptide this can be done by manually replacing the residues one by one,
54
 when 
working with proteins phage display technology is commonly used in which 
bioactive peptides or proteins are identified from combinatorial libraries of mutant 
proteins.
138,139
 
One limiting factor for the stability of peptides is the degradation of the peptide 
chain by peptidases. As there are peptidases that use either the N-terminal amino 
group or C-terminal carboxylic acid to identify a peptide before starting the 
degradation, one strategy to improve the stability can be the cyclisation of the 
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peptide by intramolecular amide bond formation.
140,141
 This cyclisation can either be 
between the termini of the peptide (head-to-tail) or between one of the termini and a 
suitable side-chain. As peptidases work by cleaving the amide bonds in the peptide 
another approach for stabilisation is N-methylation of one or more specific 
residues.
140,142,143
 However, this also results in a decrease in the hydrophilicity of the 
peptide causing problems with water solubility although it does improve the 
permeability.
117
 
A third way of modifying the structure while still retaining the peptide structure 
is the synthesis of what is called a retro-inverso peptide (Figure 6). This means that 
the sequence of the peptide is reversed at the same time as all amino acid residues 
are changed to the corresponding D-configuration. This gives a peptide with the same 
secondary structure as the original one but with the amino acid sequence inverted, 
meaning it will not be degraded by the same enzymes as the natural peptide.
144,145
 
 
Figure 6 Comparison of the structure of a natural peptide sequence A and its retro-inverso 
counterpart B 
1.4.1.1 Amide bond isosteres 
The terminology is not well defined but most commonly a pseudopeptide refers to a 
compound which still retains most of its peptide structure, but contains non-peptidic 
features. The most common starting point for designing a pseudopeptide is the 
replacement of one or more of the amide bonds. A few representative examples of 
amide bond mimetics will be given here, a more comprehensive overview of 
different mimetics and their respective properties can be found e.g. in a review by 
Gillespie et al.
146
 The changing of an amide bond is often denoted by the symbol Ψ 
followed by brackets containing the functionality replacing the amide bond. A 
number of amide bond replacements are presented in Figure 7. 
One of the oldest amide bond mimetics is the reduced amide isostere 
Ψ[CH2NH].
147
 The initial interest in these compounds is often attributed to their 
simple synthesis both in solution and on solid phase by reductive amination of 
protected aminoaldehydes.
148,149
 Use of the Mitsunobu reaction has increased the 
number of different dipeptidomimetics of this type.
150
 The use of reduced amides 
improves both the metabolic
149,151
 and chemical
152
 stability of peptides. The 
increased basicity of the reduced amide as compared to the original amide can be a 
source for problems as it increases the polarity of the pseudopeptide which can 
potentially affect its pharmacokinetic and receptor-binding properties adversely. One 
possibility for avoiding this problem is to use the structurally similar ketomethylene 
isostere (Ψ[COCH2]). Introducing a ketomethylene unit in a tripeptide does not 
change the affinity of the compound for the human intestinal peptide transporter, 
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hPEPT1, that is responsible for the active transport of peptides and peptidomimetics 
over the apical membrane.
153
 Ketomethylene units are also successful amide bond 
replacements in several protease inhibitors,
154,155
 at least one of which (AG7088 or 
rupintavir) has been clinically evaluated as an irreversible inhibitor of human 
rhinovirus (HRV) 3C protease
156,157
 and is also a promising antiviral for combating 
enterovirus 71.
158
 Ketomethylenes units can be easily synthesised using a tandem 
chain extension aldol reaction
153,159
 and are also found in natural peptides such as the 
aminopeptidase B inhibitors arphamenine A and B that have been isolated from 
bacteria.
160 
 
Figure 7 Selected examples of amide bond replacements.  
One common amide bond isostere is the alkene Ψ[-CH=CH-], both in the E- and Z-
configuration. Of these two, the E-isomer is the more popular one as it closely 
mimics the trans-geometry seen in most amide bonds.
161,162
 The Z-isomer of the 
double bond mimics the cis-geometry of an amide bond equally well, although this 
type of amide is typically only found in –Aaa-Pro-bonds.163 Of special interest 
among the alkenes are the fluoroalkenes (Ψ[-CF=CH-]) as these also retain most of 
the polarity of the original amide bond.
164
 An interesting modification of the 
fluoroalkene-moiety as an amide bond isostere is the trifluoromethylated analogue 
(Ψ[-C(CF3)=CH-]) which exhibits an improved mimicry of the electrostatic potential 
surface of the amide bond and also mimics its dipole moment.
161
 A step closer to the 
properties of the original peptide bond is Ψ[-CH(CF3)NH-]. In addition to the CF3-
group being electronically similar to the carbonyl, this mimetic has a backbone angle 
close to the 120° of an amide bond as well as having a pKa-value closer to that of the 
NH of the CONH group.
165,166
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Another example of constructing pseudopeptides is to use the so-called 
azapeptides in which the α-carbon is replaced by a non-stereogenic nitrogen yielding 
a rigid urea structure (Figure 8). An interesting feature of the azapeptides is that they 
appear to favour the formation of turns.
167,168
 A large number of bioactive 
azapeptides have been prepared
168
 and proven to retain their biological activity.
169 
One approach for the design of pseudopeptides are the peptoids in which the 
amino acid side-chain has been shifted from the α-carbon to the amide nitrogen, 
forming an N-substituted polyglycine chain (Figure 8).
170
 This gives a structure with 
a significantly more flexible backbone allowing it to adapt both the cis- and trans-
conformation of the amide bond.
171
 Partial replacement of the sequence of the parent 
peptide with peptoid moieties has yielded both a nociceptin antagonist
172
 and β-sheet 
breakers able to inhibit amyloid formation.
173 
 
Figure 8 Structural changes to the peptide backbone in azapeptides and peptoids. 
In addition to the methods already presented for the design and synthesis of 
pseudopeptides, several modifications also exist that are based on an elongation of 
the peptide backbone. These include, but are not limited to, β-peptides,174 vinylogous 
peptides,
175
 ureas
176
 and carbamates.
177
 Such structures are shown in Figure 9. 
 
 
Figure 9 Various examples of backbone modifications in pseudopeptides. 
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1.4.1.2 Disulphide bridge mimetics 
As disulphide bridges are both important for the 3D structure of peptides and 
proteins and are metabolically scissible, they make an interesting target for the 
modification of peptides into more stable analogues. The use of hydrocarbon bridges 
has been found to be both simple to introduce in the structure and to retain the 
biological activity of the parent peptide.
178-182
 Other alternative modifications of the 
native disulphide bridge include replacing the sulphur atoms with selenium or 
tellurium,
183
 introducing lactams for cyclisation,
184
 fully reduced hydrocarbon 
linkers,
185
 or the use of triazoles formed by click-methodology.
186
 
The simplest way of introducing an unsaturated hydrocarbon linker in a peptide 
is to incorporate two or more allylglycine residues in the amino acid sequence, these 
residues can later be coupled using a ring-closing metathesis (RCM) reaction to yield 
the cyclic pseudopeptide containing the same number of atoms in the bridge as the 
native disulphide. One problem with this approach is that, given the larger size of the 
sulphur compared to the carbon atom (100 and 70 pm in diameter, respectively)
187
 
and hence the greater length of both the S-S and S-C bond than their C-C counterpart 
(2.0 Å, 1.8 Å and 1.5 Å, respectively),
188
 the length of a four-carbon bridge will not 
be equal to a regular disulphide bridge containing two carbons and two sulphurs. The 
disulphide bond will usually adopt a cis-like conformation with a roughly 90° 
dihedral angle between the C-S bonds which further complicates a direct 
comparison. Comparing the energy minimised structures of peptide hormone 
oxytocin and an analogue containing a cis double bond in place of the disulphide 
bridge shows a high level of similarity, the only major difference is a small kink in 
the disulphide bridge caused by the 90° dihedral angle between the sulphur atoms 
 
Figure 10 Overlaid energy minimised structures of oxytocin (A) and an analogue 
containing a hydrocarbon linker with a cis double bond in place of the 
disulphide bridge (B). Side chains on Y, I, Q, N, L are omitted for clarity. 
Reprinted with kind permission from ref 179. Copyright © 2005 American 
Chemical Society 
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 (Figure 10).
179
 The analogue containing the cis double bond had a biological activity 
approximately 10-fold lower than oxytocin whereas the analogues containing the 
trans double bond or the fully saturated linker were 100-fold less active than the cis 
linker.
178,179
 
Despite these facts a common approach to replacing disulphide bridges is to use a 
trans-double bonded four-carbon linker that is often formed in situ by using the 
RCM reaction during the peptide synthesis. Even though the length of the linker 
itself may not be the same as the length of a native disulphide bridge, the differences 
in the conformation of the bridges means that the more rigid alkene-based bridge 
may well give the pseudopeptide a conformation in which the α-carbons are at the 
same distance from each other. 
1.4.1.3 Secondary structure mimetics 
The properties of peptides and proteins are largely defined by their secondary 
structure. Common subunits found are β-strands, -turns, -sheets, and α-helices. 
The simplest of these subunits is the β-strand which is a peptide chain in which 
the backbone is completely stretched out with the side chains of the residues 
protruding on alternating sides. Even though β-strands have for a long time been 
considered to be merely random structure elements in peptides, it has been shown 
that enzymes use β-strands to identify and bind substrates or inhibitors, thus making 
β-strand mimetics attractive as enzyme inhibitors.136,137 Additionally, the immune 
system also routinely uses β-strands for recognition and destruction of infected 
cells.
189,190
 Even though only a few amino acid residues are often responsible for the 
biological activity associated with a β-strand, the flexibility of short peptides will in 
most cases mean that a fragment containing only these residues is unlikely to adopt 
the correct conformation and will hence lack the biological activity of the parent 
peptide. If this is the case, the structure can be rigidified by e.g. the introduction of 
macrocyclisation (end-to-side chain and/or using unnatural amino acids) as in 
pseudopeptide 8 that mimics 12 different linear HIV-1 protease inhibiting peptides 
or pseudopeptides.
191
 Another altenative is to introduce nonpeptidic elements to 
replace amino acid residues as in tetrapeptide mimicking p21
ras
 farnesyltransferase 
inhibitor 9.
192
 
 
A β-sheet is usually formed by a right-hand turn in the peptide structure, resulting in 
so-called β-hairpin structures. The turn itself is usually referred to as a β-turn, 
meaning it consists of a four-residue nucleus stabilised by an i, i+3 hydrogen bond, 
as in 10. As the biological significance of the β-sheet is similar to that of β-strands, 
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the goal when designing mimetics or pseudopeptides based on β-sheets is also the 
stabilisation or nucleation of the secondary structure. The most common mimetics 
for nucleating β-sheets are the β-hairpin turn mimetics, also known as (β-)turn 
mimetics. The mimetics force the peptide strand to make the turn after which the 
sheet itself is stabilised by hydrogen bonding between the strands just as in the 
natural case. Examples of sheet-inducing turn mimetics are the dibenzofuran 11
193
 
and the bis-proline-derived diketopiperazine 12.
194
 Another interesting alternative for 
inducing a turn is the introduction of a D-proline residue in the amino acid sqeuence, 
thus forming 13. Even though this structure is neither a peptidomimetic nor 
technically even a pseudopeptide but should rather be classified as a modified 
peptide, it shows one of the simplest way of constructing a secondary structure 
mimetic using only natural amino acids.
195
 
 
One interesting strategy for inducing β-sheets is the use of a synthetic amino acid 
called “Hao” (named after its components: hydrazine (blue), 5-amino-2-
methoxybenzoic acid (green) and oxalic acid (red)) in a peptide which has been 
shown to allow even short pseudopeptides to adopt a β-strand conformation. When 
dissolved in chloroform these pseudopeptides readily formed β-sheet-like dimers 
(14). When these structures are fused together with a δ-linked ornithine residue to 
mimic a turn intramolecular β-sheets are formed.196 
 
One of the most abundant secondary structures in peptides and proteins is the α-
helix. The helices are important for protein-protein and protein-nucleic acid 
interactions, misregulations of these interactions often result in disease states.
197
 
Even though the biological effects of these helices mainly resides only in parts of the 
secondary structure, “hot spots” on the surface,198,199 using these short peptides as 
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drugs suffers from the same problems as any other peptides. Hence, a number of 
techniques for stabilising the helical structure of short peptides have been developed: 
nucleation of helices, surface mimetics and, most recently, stapled peptides in which 
a hydrocarbon linker is used to stabilise the structure.
200-202
 
 
As in the case of β-sheet nucleators, α-helices can also be initiated in several 
different ways. One approach is the use of non-natural residues (e.g. α,α’-dialkyl 
residues)
135
 which stabilise the peptide in the α-helix conformation. Alternatively, 
using the RCM reaction to introduce a rigid structure to replace an i,i+4 hydrogen 
bond as in 15 has been shown to be successful e.g. in forming helices inhibiting the 
gp41-mediated HIV-1 fusion (16).
203-205
 
 
Figure 11 General strategy for the synthesis of a stapled peptide
200 
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Another alternative is to use olefins attached to the side chains of selected residues to 
form a longer linker between the i,i+3, i,i+4 or i,i+7 residues which consists of 8-11 
carbon atoms, this approach is referred to peptide stapling.
206-208
 The stapled peptides 
are synthesised by SPPS by adding an α-disubstituted, non-natural amino acid (e.g. 
α-methyl-pent-4-enylglycine) and finishing the synthesis by performing the RCM 
reaction. The synthesis of these compounds is outlined in Figure 11.
200,201
 Several 
stapled peptides have been shown to have a biological efficacy similar to the parent 
peptide,
209-211
 there is even one stapled peptide that has been brought into phase I 
clinical testing.
212
 Despite this it has been reported that the stapling can destabilise 
instead of stabilise the peptide structure, possibly by disrupting the network of 
intramolecular interactions that stabilise the natural peptide.
213
 
1.4.2 PEPTIDOMIMETICS 
In contrast to both the modified peptides and pseudopeptides, a peptidomimetic is 
typically a compound which retains or mimics the biological activity of its parent 
peptide while lacking any typical peptidic elements such as peptide bonds. In 
general, peptidomimetics have improved pharmacokinetic properties compared to 
the parent peptide. IUPAC has issued the following definition:”A peptidomimetic is 
a compound containing non-peptidic structural elements that is capable of 
mimicking or antagonizing the biological action(s) of a natural peptide. A 
peptidomimetic does no longer have classical peptide characteristics such as 
enzymatically scissile peptidic bonds”.214 
Peptidomimetics are often divided into three classes. The type I peptidomimetics 
are designed to mimic the structure of the backbone of the parent peptide atom-for-
atom and retain the local topography such as a helix, a turn, or a sheet. 
Representative examples of type I mimetics are the amide bond isosteres shown in 
Figure 7 on page 13. The nature of the type I mímetics means that most of them can 
be classified as pseudopeptides. The type II mimetics are compounds that mimic the 
biological activity of a peptide while binding to a different subsite of the target 
receptor or a completely different receptor. The type III mimetics are compounds 
that bind to the same receptor as the parent peptide but no longer share any structural 
traits with it, most importantly they no longer contain any peptide bonds. Typically, 
a type III mimetic is a compound built around a template or scaffold that has been 
decorated with the side chains required for attaining the desired biological 
activity.
215
 
One of the biggest limitations in the development of bioactive compounds 
partially or completely lacking peptidic elements is the large amount of work 
required for each new compound to be developed. Even though a number of 
peptidomimetics have already been published, no general methods for the 
development of a peptidomimetic exist. A typical workflow for the de novo 
development of a peptidomimetic is presented in Figure 12. 
One approach for mimicking an α-helix using a type III peptidomimetic is the use 
of surface mimetics, i.e. non-peptidic compounds that encompass the important side 
chains from a given helix. This is based on the observation that it is often side chains  
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Figure 12 Typical workflow for the de novo approach to peptidomimetic design216 
on only one face of the helix that interact with the target, some consensus has been 
reached that the important residues are often i, i+3 or i+4, and i+7.
198,217
 As a 
consequence of this observation a number of different molecular scaffolds have been 
developed the main function of which is to present the required side chains in the 
desired orientation. In order to achieve rigidity in the backbone of the mimetic while 
retaining its helical nature, different oligocyclic compounds have been developed. 
Examples of compounds able to mimic two turns of a helix include terphenyl 
compound 17
195
 or the O-alkylated para-benzamide 18
218
 that also offers 
intramolecular hydrogen bonding to further stabilise the helical structure.
218
 It has 
however been shown that the terphenyl structure is actually not as rigid as was 
originally believed; it can adopt 16 conformations with almost equal energy. 
Because of this it was proposed that the terpyridyl scaffold 19 is actually more suited 
for this particular application.
195,219
 
 
The most complex strategy for the design of a peptidomimetic is to use a compound 
that is able to mimic the biological activity without any part of the peptide chain 
being present, a type III mimetic. In their simplest form these types of 
 21 
peptidomimetics can be a molecule that covers part of e.g. a β-sheet or an α-helix as 
compounds 20 and 21, respectively.
220,221
  
 
Once the structural requirements for a potential peptidomimetic have been identified, 
the next step in the process is usually the selection of a suitable scaffold with handles 
that make it possible to attach the required side chains in positions that allow 
interactions with the targets that are in agreement with those of the parent peptide. 
Several different scaffolds have been used in peptidomimetic applications; these are 
often based on some type of cyclic core to limit the flexibility of the final compound. 
Some examples of the cyclic scaffolds used are cyclohexane,
222
 sugars,
223
 
triazoles,
224
 oxadiazoles,
224
 diketopiperazines,
225
 chromones,
226,227
 
chromanones,
226,228
 quinolones,
229
 isoindolones
230
 and tricyclic ring-fused 
pyrazoles.
231
 
Often the peptidomimetic is designed to fit into a specific receptor or active site 
on e.g. an enzyme and not to specifically mimic a certain peptide, although if both of 
these pieces of information are available, they can be combined to create the final 
mimetic. The design of a peptidomimetic is often based around a cyclic, preferably 
heterocyclic, scaffold that is used to direct the side chains necessary for the 
biological activity into the position required to fit into the target. Several different 
compounds based around different scaffolds have been found to have biological 
effect with several different targets. Examples include the 2-pyridone based pilicide 
22
232
 (mimicking the C terminus of PapG, an adhesin involved in the disease process 
of uropathogenic infections) and HRV 3C protease inhibitor 23 that mimics a 
synthetic hexapeptide substrate of the enzyme,
233
 chromone 24 that mimics a Gly- 
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Tyr-Phe-Gly β-turn,226 and the benzazepin-3-one based human melanocortin-3 
receptor ligand 25 that mimics the tetrapeptide (His-Phe-Arg-Trp) that has been 
found to contain the principal pharmacophore groups of α-melanocyte stimulating 
hormone (α-MSH).234 
In some cases, when the starting point is a small cyclic peptide, a peptidomimetic 
can be designed that accurately mimics the entire structure of the peptide. An 
example of this is the design of mimetic 26 based on the structure of rhodopeptins 
C1 and B5 illustrated in Figure 13.
229,235
 
 
Figure 13 Design of scaffold peptidomimetics based on rhodopeptins C1 and B5. 
1.4.3 PRIVILEGED STRUCTURES 
One central concept in drug discovery that applies well to peptidomimetics is the 
idea of privileged structures. This concept was introduced by Evans et al. who in 
1988 stated that “certain privileged structures are capable of providing useful 
ligands for more than one receptor”.236 What this phrase means in practice is that it 
has been observed that there are some recurring structures that can be found in drug 
molecules and biologically active compounds acting on different targets. 
The concept of privileged structures is one that is largely concerned with 
molecular frameworks. The original idea presented by Evans and coworkers stems 
from the investigation of benzodiazepine derivatives and the discovery that these 
compounds have an antagonistic effect on the peptide hormone cholecystokinin A 
(CCK) as well as the benzodiazepine receptor. These compounds are built around the 
benzodiazepine core 27; the compounds in Evans’ study are further based on 
prototype compound 28.
236
 This work has later been expanded first by Bunin et al. 
who screened 192 compounds against CCK
237
 and later by Thompson and Ellman 
who screened 1680 1,4-benzodiazepines and also found biological activity for 
additional targets.
238
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To identify privileged frameworks in drug molecules, Bemis and Murcko have 
proposed a systematic approach for breaking a compound down into its constituent 
parts (Figure 14).
239
 
 
Figure 14 Strategy for hierarchical breakdown of a drug molecule239 
The antidepressant thioridazine 29 can be used as an illustrative example of this 
process. In 30 the different parts of the structure have been colour-coded for clarity. 
The side chains are black and the graphic framework of the molecule has been 
divided into the red ring systems and green linker part. When illustrated in this way 
it is clear that the graphic framework in this particular compound consists of two 
cyclic units connected by a two-carbon linker (the red and green parts of 30). 
Whether or not the framework can be considered to be a privileged structure is 
defined by how frequently it is found among bioactive or drug compounds.
239
 
 
 
In order to investigate structures that are common in drug compounds, Bemis and 
Murcko screened 5120 compounds from the Comprehensive Medicinal Chemistry 
(CMC) database.
239
 From this set of compounds it was possible to define 32 
simplified or graphic frameworks that account for around 50 % of the total number 
of molecules. When additional properties such as atom hybridisation, type and bond 
order are also considered 41 atomic frameworks account for 24 % of the compounds. 
Although benzene is clearly the most common structure (433 compounds, 8.5 %) it 
is still clear that other cyclic structures are also abundant among drug molecules, 
including both carbo- and heterocyclic ring systems (Figure 15). In order to further 
refine the concept of privileged structures, Feher and Schmidt performed a statistical 
analysis of around 710 000 biologically active compounds from several databases 
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and were able to identify a number of numerical descriptors such as molecular 
weight and number of heteroatoms.
240
 
 
Figure 15 Examples of atomic frameworks and their respective number of hits in the CMC 
database
239
 
 
Han et al. used the information available on privileged structures to construct a set of 
29 bicyclic (both fused and linker-connected) scaffolds to identify around 160 
compounds from four different databases and study their physicochemical and 
pharmacokinetic properties.
241
 The properties of these compounds were investigated 
by modelling and verified by data from the literature where this was possible. In 
order to construct a model for predicting the properties of new compounds, the cell 
permeability was tested with Caco-2 cells and the metabolic stability with rat liver 
microsomes. Combining all the data made it possible to formulate some drug-like 
ranges for several descriptors of potential drug compounds. The conclusion could 
also be drawn that bicyclic compounds containing heteroatoms do have advantages 
over other types of structures when designing drug compounds. 
Even though the privileged structures mostly appear in discussions on the drug-
likeness of compounds they can also be utilised in the design of experimental 
procedures. This is exemplified in a comprehensive review on the combinatorial 
synthesis of compounds based on privileged structures and substructures.
242
 
What conclusions can be drawn from this discussion? The consensus among 
researchers working in this field is, in short, that the concept of privileged structures 
can be useful when designing new compounds although it does have its flaws. What 
is clear is that there are molecular frameworks that are found in a large number of 
different drug compounds and natural compounds,
236,239,241
 that compounds based on 
the same framework can have an effect on several different targets
236,242
 and that 
some physicochemical descriptors such as molecular weight, polar surface area and 
number of hydrogen bond donors and acceptors have ranges where it is more 
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probable to find biologically active compounds.
241,243,244
 Even though no rules of this 
type can, on their own, guarantee the success of a drug compound, consideration of 
these and other factors can greatly increase the probability of achieving biological 
activity.  
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2 AIMS OF THE STUDY 
As the proteolytic activity of KLK3 seems to play a role in the development and 
progression of prostate cancer it is an attractive target for a medicinal chemistry 
project. Stimulating the proteolytic activity of KLK3 is an especially interesting 
target as it has been shown to have an antiangiogenic effect directly related to this 
activity. At the moment, however, the only compounds known to efficiently 
stimulate this activity are peptides 4-6 identified by phage display technology. In 
order to exploit this extremely interesting biologicial activity it is necessary to 
develop new compounds with the same activity as the peptides but with improved 
pharmacokinetic properties. 
The aim of this work was to use the C-4 and B-2 peptides (4 and 5, respectively) 
as a starting point and develop pseudopeptides that exhibit the same biological 
activity as the parent peptides while being more stable in vivo. The ultimate goal of 
the project was to further refine the information from the study of the peptides in 
combination with molecular modelling studies to develop a small molecular 
peptidomimetic with the same biological activity as the peptides.  
 
More specifically, the aims of the work were to: 
 
 Develop orthogonally protected hydrocarbon crosslinks that can be used 
as building blocks to mimic a disulphide bridge. 
 Investigate which amino acid residues in the C-4 peptide are necessary 
for retaining its biological activity. 
 Develop a protocol to introduce said building blocks in pseudopeptides 
stimulating KLK3 using SPPS or other methodology. 
 Develop a scaffold based, small molecular peptidomimetic stimulating 
KLK3.  
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3 PSEUDOPEPTIDES STIMULATING KLK3 
(PAPERS I-III) 
3.1 REPLACING A DISULPHIDE BRIDGE WITH A 
HYDROCARBON LINKER 
The most potent KLK3 stimulators known so far are peptides C-4 (4), B-2 (5), and 
A-1 (6). Interestingly, previous work has shown that 4 and 5 can be modified 
without a significant loss in biological activity.
54,55
 This makes them interesting as 
starting points for the development of pseudopeptides. Previous results also indicate 
that at least in peptides 4 and 5, the residues closest to the disulphide bridges are 
important for retaining the biological activity.
54
 
Even though it has long been known that disulphide bridges in biologically active 
peptides can be replaced without a significant loss in biological activity,
185
 only the 
development of synthetic methodologiy has made it possible to utilise the full 
potential of these types of modification in the development of peptide-based drugs. 
These factors indicate that an interesting starting point for modifying KLK3 
stimulating peptides is the replacement of the disulphide bridge (or bridges) in 4 or 
5. There are several reasons for this:  
 Some information is already available on which parts of the peptides are 
important for the biological activity 
 The stability of 5 in plasma can be increased by removing the terminal 
NH2 group without losing biological activity 
 Replacing disulphide bridges with hydrocarbon linkers in peptides does 
not generally result in a significant lowering of the biological effect of the 
peptide 
 The use of different hydrocarbon linkers can offer further insights into 
how the conformation of the disulphide bridge affects the biological 
activity of the peptides 
 It presents a significant challenge in synthetic chemistry 
3.1.1 DISULPHIDE-BRIDGE MIMICKING BUILDING BLOCKS (PAPER I) 
The C-4 peptide (4) contains two potentially labile disulphide bridges and as alanine 
replacements have shown that the residues required for biological activity are 
situated around the central bridge, it was of interest to construct a synthetic protocol 
for replacing at least this one. We also wanted to develop a general method that 
could be applied to other peptides as well. In order to accomplish this, we envisioned 
constructing four orthogonally protected building blocks based on 2,7-
diaminosuberic acid 31, the two different conformations of 2,7-diamin-oct-4-
enedioic acid 32a/b and 2,7-diamin-oct-4-yndioic acid 33. 
Although these core structures are known in the literature, only 31 has previously 
been reported to have been synthesised in an orthogonally protected form.
245
 Aside  
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from the protecting groups used not being the ones required for the rest of our 
synthesis, the procedure for obtaining the product was also rather cumbersome. The 
key step in this procedure, outlined in Scheme 1, is a mixed Kolbe electrolysis 
yielding a mixture of the three possible products in a 1:2:1 ratio.
245,246
 According to 
the literature the total yield of the desired cross-coupling product from this reaction 
was 12.3 %.
245
 
 
Scheme 1 Mixed Kolbe electrolysis for obtaining an orthogonally protected building block.
245
 
Other methods for the synthesis of similar compounds have also been reported using 
Schöllkopf bislactim ether methodology,
247
 alkyne cross metathesis
248
 and Katsuki-
Sharpless asymmetric epoxidation
249
 as the key steps for sythesising the final 
product. All of these methods do produce enantiopure products but the overall yields 
are limited both by the number of synthetic steps needed and the complex starting 
materials. All of the reactions are also limited to only one final product (the fully 
saturated linker) meaning that the other linkers needed cannot be accessed using 
these methods and the methods can hence not be called general. 
Methods can be found in the literature for the synthesis of similar building blocks 
containing both the alkene,
181,250,251
 the alkyne
252
 and the fully reduced chain
250
 with 
non-orthogonal protecting groups. In some previously published cases the authors 
have not determined the orientation of the double bonds in the alkene products, 
possibly due to the main interest being the fully reduced analogue, meaning that the 
double bond was reduced in the following step in these studies. 
In addition to the need for the protecting groups used to be orthogonal, they also 
had to be compatible with the Fmoc-protocol used in SPPS. This meant that a 
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method was needed that enabled the selective removal of the methyl ester and 
phthalimide protecting groups that are not normally used with this protocol. 
The method chosen for the synthesis of the required disulphide bridge mimetics 
employs a copper-mediated organozinc/haloalkyne reaction originally published by 
Yeh and Knochel in 1989
253
 to form alkyne building block 36 (Scheme 2). The same 
method has also previously been employed in the synthesis of the non-orhogonally 
protected form of linker 33 with the NH2 groups Boc-protected and the carboxylic 
acids protected as methyl esters.
252
 Once the reaction was found to work 
satisfactorily, attempts were made to modify the reaction conditions to improve the 
yield but neither altering the copper source to CuBr·DMS (32 % yield) nor changing 
the solvent to THF (<10 % yield) were successful. 
Building block 32 was found to be readily reduced by catalytic hydrogenation 
using either Rosenmunds catalyst (Pd on BaSO4) or Pd/C to give the Z-double bond 
37 or the fully saturated 38, respectively (Scheme 2). Attempting the selective 
reduction to the Z double bond using Lindlar’s catalyst did not yield the desired 
product. Both starting materials (34 and 35) are readily available through well-
established reactions from commercially available starting materials.
254-256
 
 
Scheme 2 Synthesis of alkyne linker 36 and its subsequent reduction to the Z-alkene and 
alkane analogues. 
Once building block 36 had been synthesised, the orthogonality of the protecting 
groups was proven by the selective removal of each one to access the four different 
mono-deprotected linkers. The Fmoc moiety was removed using diethylamine and 
the Boc group by hydrolysis using hydrochloric acid in ethyl acetate, both using 
standard methods. The selective hydrolysis of the methyl ester turned out to be more 
complicated; using lithium hydroxide resulted in an unsatisfactory yield as well as 
partial cleavage of the Fmoc group. Fortunately, it was possible to selectively 
hydrolyse the ester in good yield by using trimethyltin hydroxide in 1,2-
dichloroethane at 60 °C, conditions reported by the Nicolau group.
108
 The removal of 
the tert-butyl ester to give carboxylic acid 41 required a two step strategy including 
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the removal of both acid-labile protecting groups followed by reprotection of the 
amine as a phthalimide.
‡
  
 
Scheme 3 Synthetic strategies for the selective mono-deprotection of alkyne linker 36. 
In order to have a complete set of the different linkers, a method was also needed for 
synthesising the linker containing the E-alkene (45). As there are no methods 
available in the literature for selective reduction of an alkyne to an E-alkene, a 
different method for this synthesis was needed. For this purpose, the cross metathesis 
(CM) reaction was employed using conditions found in the literature,
257
 which 
afforded the desired product in good yield (Scheme 4). Using microwave instead of 
thermal heating proved disadvantageous as the yield decreased from 57 % to 36 %. 
Lowering the loading of catalyst 46 from 10 % to 5 % decreased the yield to 46 %. 
 
Scheme 4 The CM reaction used for synthesis of the E alkene-containing linker 45. 
                                                 
‡ The phthalic anhydride used for the reprotection step was old and partly decomposed which may 
have lowered the yield of this step. This was discovered after the completion of the syntheses and was 
not investigated further. 
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Interestingly, the only product isolated after the CM reaction was the cross-coupling 
product 45. This is in stark contrast to previous investigations where the CM reaction 
has been shown to exclusively give homodimers when two different allylglycine 
derivatives are present in the reaction.
181
 By following a similar reaction by NMR 
spectroscopy, Schmidtmann and coworkers have shown that the reaction initially 
forms a homodimer of one of the starting materials which then undergoes a second 
CM reaction to form the final product; as illustrated in Scheme 5.
251
 One exception 
to this is the use of the CM reaction to either couple two allylglycine residues that 
are part of a pseudopeptide or the coupling of an allylglycine to another, resin-
bound, allylglycine residue.
180
 In these cases, formation of heterodimers has been 
reported. Such reactions will be further discussed in the following chapter. 
 
Scheme 5 Proposed route for the formation of a heterodimer via a CM reaction.
251
 Bold 
reaction arrows indicate the presumed reaction pathway. 
In order to investigate how the length of the hydrocarbon chain in the linker impacts 
the biological activity of the pseudopeptides, we also investigated the possibilities 
for synthesising linkers containing more that four carbon atoms. (Unpublished 
results) Of special interest were linkers 47 - 50 that are five carbon atoms long as 
these should be roughly equal in length to their sulphur-based parent structures. 
Bridges shorter than four carbons are most probably too short to be able to 
accurately mimic the structure of the disulphide bridge and were excluded from 
these considerations. 
 
In order to access these compounds, we wanted to use similar chemistry as the 
methods that had been used to synthesise the orthogonally protected building blocks 
discussed earlier in this chapter. In addition to investigating the viability of the 
reactions in question with different starting materials, this also required starting 
materials containing an additional carbon atom. In the case of the CM reaction this 
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means replacing one of the allylglycines in the reaction with 2-amino-5-hexenoic 
acid 51. Even though this compound is available from commercial sources, the price 
makes it more attractive to synthesise, especially as a simple procedure for this is 
well known in the literature.
258,259
 For building block 48 containing the triple-bonded 
linker, we opted to extend the chain using iodo-homoserine (2-amino-4-iodobutanoic 
acid) 52 instead of 2-amino-5-hexynoic acid 53. Even though both of them are 
known in the literature, 52 only requires the protection and iodination of commercial 
homoserine whereas 53 requires more complex chemistry.
260
 
 
With the starting materials in hand, both of the coupling reactions were attempted. 
Even though our previous syntheses of orthogonally protected building blocks using 
the CM reaction had run smoothly, the coupling outlined in Scheme 6 was more 
complicated than anticipated. NMR-spectroscopic analysis of the product mixture 
from the CM reaction did show the desired product in decent yield, unfortunately all 
attempts at purifying the product resulted in inseparable mixtures of two compounds. 
The original theory that these two compounds would simply be isomers containing 
the two different double-bond orientations was easily disproven by a catalytic 
hydrogenation of the mixture that also gave a mixture of two compounds. What is 
worth noting in this context is that even though the CM reaction using α-3-
butyleneglycine 51 as one component seems to be unsuccessful, several reports exist 
detailing using this when cyclising pseudopeptides via the RCM reaction.
179
 
 
Scheme 6 Proposed CM reaction to form a building block containing a five-carbon linker 
 
Scheme 7 Attempted Cu-mediated coupling to access longer alkyne-based linkers. 
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A similar attempt at synthesising a longer building block (55) by using copper 
chemistry was even less successful (Scheme 7). Using the same conditions for the 
reaction that were used previously failed to yield any product. This lack of success in 
synthesising building block 55 also meant that the building block corresponding to 
50 was out of reach as it would have been synthesised by reduction of 55. 
3.1.2 INTRODUCTION OF A HYDROCARBON LINKER IN THE C-4 
PEPTIDE USING RING-CLOSING METATHESIS (PAPER II) 
One of the objectives of the thesis was to complement the information gained from a 
previous single-alanine replacement study
54
 to build a more detailed picture of which 
amino-acid residues are important or necessary for the KLK3-stimulating activity of 
peptide 4.  
In order to achieve this goal, a number of peptides were synthesised and their 
biological activity evaluated. In the first study, it was shown that residues Glu7, His8 
and His9 could be replaced with alanine without a significant loss in biological 
activity.
54
 These results were further expanded in our second study (Paper II). Ile6 
was also replaced with other non-polar residues which led to the interesting 
observation that this residue could be replaced with amino acids with lipophilic side 
chains, whereas residues with smaller side chains such as alanine and glycine were 
not tolerated. The results from the multiple-alanine scan are listed in Table 1. 
Table 1. KLK3 stimulating effect of analogues of peptide 4 in the multi Ala-replacement 
study.Concentration of all peptides in the assay was 20 µg/ml. 
 
a
amino acid replacements are marked in bold face; 
b
the activity of KLK3 alone is 100 %  
From these results it was possible to conclude that the residues next to both 
disulphide bridges seem to be important for the biological activity of the peptide. 
Peptide Replacements
a 
KLK3 proteolytic 
activity [%]
b 
56  226 
57  476 
58  239 
59  165 
60  84 
61  127 
62  583 
63  436 
64  299 
65  152 
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Based on this, the internal disulphide bridge was considered to be most important for 
the development of pseudopeptides. 
Our first thought was to use the previously synthesised building blocks directly 
in solid-phase peptide synthesis to replace the internal disulphide bridge of 4. The 
simplest strategy for the synthesis of the target peptide is to use mono-deprotected 
linker 41 and couple this to the resin-bound tripeptide Cys13-Thr12-Trp11 using 
standard peptide coupling conditions (but using a longer coupling time). The peptide 
synthesis is then continued normally to the Ile6-residue, the methyl ester and Fmoc 
groups in intermediate 66 are removed and the ring is closed using a head-to-tail 
peptide coupling. The phthalimido protecting group is removed and the peptide 
synthesis is completed by the addition of the three remaining residues. Finally, the 
pseudopeptide is cleaved from the resin and the terminal disulphide bridge is closed 
by oxidation using I2 in acetic acid with aqueous HCl. Unfortunately, the hydrolysis 
of the methyl ester and/or the cleavage of the phthalimido group in 66 was 
unsuccessful despite several different attempts and methods. 
 
 
This initial failure required the development of another method for synthesising 
pseudopeptide analogues of peptide 4. In our second attempt, tetrapeptide 67 was 
synthesised in solution before coupling to building block 68. As racemisation of the 
histidine residue after coupling the tetrapeptide to the building block was observed, 
all of the isolated products were closely examined by NMR spectroscopy after 
purification. With the help of these analyses it was concluded that the addition of 
EDC∙HCl was required to suppress the racemisation and it was possible to isolate 
cyclic pseudopeptide 70 in pure form.  
Disappointingly, the hydrolysis of the methyl ester, which is required for the 
continued peptide synthesis failed even when using trimethyltin hydroxide in 1,2-
dichloroethane, a procedure previously found to selectively hydrolyse the methyl 
esters of orthogonally protected building blocks 36 and 45 without any cleavage of 
the Fmoc group. The reason for this is believed to be the steric hindrance caused by 
the Fmoc- and trityl groups close to the methyl ester in the non-polar solvent.  
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Scheme 8 Solution phase synthesis of the smaller ring of the C-4 peptide 
Several different explanations for this observation were initially considered and 
molecular modelling of the compound was used to attempt to further elucidate the 
problem. This showed that the pseudopeptide will likely adopt a conformation 
wherethe Fmoc- and/or trityl groups twist close to the methyl ester creating 
significant steric hindrance around the carbonyl group of the ester. As trimethyltin 
hydroxide is also a bulky reagent
261
 it appears unlikely that it would have the access 
to the carbonyl group required for the reaction to take place. A smaller reagent such 
as lithium hydroxide might be more successful at hydrolysing the ester, but as this 
could also lead to cleavage of the much more accessible Fmoc group, it is not an 
approach that is useful in this specific application. Thus the conclusion from this 
discussion was that this is not a track worth pursuing any further and a completely 
different approach was needed. 
Inspired by the recent success of using ring-closing metathesis (RCM) to cyclise 
a number of different pseudopeptides,
262
 it was also decided to investigate the 
applicability of this approach to the problem at hand. In the initial attempt, the entire 
sequence of the target peptide was synthesised on Wang resin using standard Fmoc-
chemistry. Peptide 71 was cleaved from the resin and subjected to RCM conditions 
(Hoveyda-Grubbs 2
nd
 generation catalyst (HG2), trifluoroethanol:DCM 4:1, RT, 
24h) which unfortunately did not give even trace amounts of the desired product. 
The same procedure was also tried for resin-bound pseudopeptides 72a and 72b but 
the results were equally disappointing. Altering reaction times (24 or 48 h) or 
temperature (room temperature or 60 °C) or changing the catalyst to the Grubbs 2
nd
 
generation catalyst 46 did not prove beneficial either. Performing the RCM reaction 
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on a resin-bound pseudopeptide fragment 73 where the synthesis was halted after 
addition of the second allylglycine residue also failed to produce any product, the 
different conditions used are listed in Table 2. 
 
 
Figure 16 One possible conformation of peptide intermediate 70. For clarity, the methyl ester 
is coloured purple, the Fmoc group red and the trityl green. 
 
A search in the literature revealed that other groups facing similar problems had been 
able to overcome them by the addition of LiCl in DMF to the RCM reaction. The 
published procedures were modified slightly and the reaction was performed on 
intermediate 73 at 100 °C in 1,2-dichloroethane for 1 h with microwave heating. 
After cleaving the peptide from the resin we were pleased to find that the mass 
spectrum (MS) of the crude product showed mainly cyclised peptide, the only by- 
products were minute quantities of unreacted starting material. The reaction was 
repeated for intermediates 74 and 75; the peptide synthesis was finished, the peptides 
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were cleaved from the resin, cyclised at the terminal disulphide bridge and purified 
by HPLC. 
Table 2. Reaction conditions tested during optimisation of the RCM reaction. 
Starting 
material 
Catalysta Additiveb Solventc Temperatured 
[°C] 
Time [h] Producte 
71 HG2  TFE:DCM 4:1 RT 24 nd 
72a HG2  TFE:DCM 4:1 RT 48 nd 
72b HG2  DCM RT 24 nd 
72b HG2  TFE:DCM 4:1 60 1 nd 
72b HG2  DCM 60 1 nd 
72b HG2  DCE 60 20 nd 
72b G2  DCE 60 20 nd 
72b HG2 LiCl/DMF DCE 100 (MW) 1 nd 
72b G2 LiCl/DMF DCE 100 (MW) 1 nd 
73 HG2  DCE RT 48 nd 
73 HG2 LiCl/DMF DCE 100 (MW) 1 > 50% conv. 
74 HG2 LiCl/DMF DCE 100 (MW) 1 > 50% conv. 
75 HG2 LiCl/DMF DCE 100 (MW) 1 > 50% conv. 
aHG2, Hoveyda-Grubbs 2nd gen. catalyst; G2, Grubbs 2nd gen. catalyst; bDMF, N,N-dimethylformamide; cTFE, 
trifluoroethanol; DCM, dichloromethane; DCE, 1,2-dichloroethane; dRT, room temperature; MW, microwave 
heating; end, not detected by MS; conv., conversion in comparison to unreacted starting material by MS. 
 
Scheme 9 RCM reaction and final SPPS to give pseudopeptide analogues of 4. Materials and 
methods: a) HG2, 0.4 M LiCl in DMF (10% (v/v)) / DCE, 100°C, MW; b) i. SPPS 
(coupling of Tyr(
t
Bu), Ala, Val and Cys(Acm)), ii. Reagent K 
(TFA:H2O:phenol:thioanisol:EDT 82.5:5:5:5:2.5); c) I2, HCl / AcOH, H2O. 
The main drawback of using this strategy is that the reaction forms a mixture of the 
E- and Z-isomers of the double bond and that there is no way of controlling this 
ratio. It is also unlikely that it will be possible to separate the peptides containing the 
two different isomers. It is, however, possible to determine the ratio of the two 
isomers using NMR-spectroscopy.
263,264
  
A close examination of the NMR spectra of both the peptide cleaved after the 
RCM reaction and the purified final product showed that the ratio of the E and Z 
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isomers in the products is roughly 1:1. The NMR spectrum of peptide intermediate 
74 after the RCM reaction is shown in Figure 17. 
 
Figure 17 NMR spectroscopic analysis of the double bond in peptide intermediate 74 after the 
RCM reaction. 
Even though papers can be found where alkene-containing disulphide mimetics in 
terminal position have been reduced using standard H2, Pd/C-methodology,
178,179
 
none seem to exist when the disulphide bridge is internal. Inspired by this, several 
attempts were made at reducing the double bonds in the pseudopeptides using 
hydrogen gas and a suitable catalyst. The reducuction of the double bonds in the 
pseudopeptides is also motivated by the observation that the peptides we synthesised 
contain a mixture of the two isomers of the double bond. Under the assumption that 
the peptides with the different double bonds will not be equally active it is also 
difficult to assess the actual potency of the pseudopeptides when they can only be 
tested as a mixture. 
The reduction of the pseudopeptides was attempted both using standard solution-
phase methodology (a balloon of H2) and using a continuous flow hydrogenation 
reactor that makes it possible to run reactions both at elevated temperatures and 
under a hydrogen pressure of up to 100 bar. The reactions were attempted both with 
regular and elevated pressure of hydrogen and the material was cycled through the 
catalyst several times. The catalysts used were Pd/C and Raney nickel. 
Unfortunately, MS analysis did not show any trace of the desired product. Reduction 
of only the smaller ring 70 gave essentially full conversion of starting material to 
product (as determined by MS), thus proving the general viability of the method 
itself. 
Finally, the biological activity of the pseudopeptides was evaluated compared to 
the parent peptide. The results, presented in graphical form in Figure 18, were 
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encouraging for the continuation of the project. Our new pseudopeptides 76-78 
increased the activity of KLK3 to 225 %, 189 % and 223 %, respectively, of that of 
KLK3 alone. This can be compared to an increase in activity to 625 % by peptide 4. 
All of the previous results were obtained at a peptide concentration of 20 µg ml
-1
 
(corresponding to 13 µM for 4, 76 and 77, and 14 µM for 78). When increasing the 
concentration of the pseudopeptides to 200 µg ml
-1
, they reached a level of 
stimulation approximately fourfold to that of KLK3 alone. It is, however, unclear at 
present if this is an absolute maximum or if higher concentrations would give an 
even higher level of stimulation. It is also possible that the simulation of KLK3 is 
only caused by the peptide containing one of the two isomers of the double bond, 
this could account for the seemingly lower potency of pseudopeptides 76-78 
compared to 4. 
 
Figure 18 Dose response curves of pseudopeptides 76-78 compared to parent peptide 4 
3.1.3 REPLACING THE DISULPHIDE BRIDGE IN PEPTIDE B-2 WITH A 
HYDROCARBON LINKER (PAPER III) 
Based on the success of pseudopeptides 76-78 bearing a hydrocarbon linker in place 
of a disulphide bridge, we wanted to further elaborate this finding by producing 
pseudopeptides containing only one isomer of the double bond and also the fully 
saturated linker in place of the disulphide bridge. As our original attempt at using our 
previously synthesised building blocks failed due to problems with the removal of 
protecting groups, we instead decided to direct our attention towards the monocyclic, 
KLK3 stimulating, peptide B-2 (5). As a previous investigation showed that a 
peptide lacking the N-terminal amino group retains its biological activity and 
displays a higher stability both in the presence of KLK3 and in plasma,
55
 we also 
wanted to expand our set of building blocks to cover this type of structure. The set of 
target compounds was thus pseudopeptides 79a-79d. 
Pseudopeptides stimulating KLK3 (Papers I-III) 
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The building blocks for 79a and 79b were synthesised following the CM-based 
procedure already described. The only difference was that the fully reduced building 
block was synthesised by a reduction of the E-alkene before hydrolysis of the methyl 
ester. 
 
 R Linker 
5 NH2 
 
79a NH2 
 
79b NH2 
 
79c H 
 
79d H 
 
 
The building block for the pseudopeptide lacking the terminal amino group was also 
synthesised in a similar way, the only modification to the procedure was the 
replacement of one of the allylglycines in the CM reaction with methyl 4-pentenoate 
80b (Scheme 10). These methods gave us easy access to all four building blocks 
required. Unfortunately, using the CM reaction for this procedure resulted in 
building blocks with an inseparable, roughly 3:1 mixture of the E and Z double bond 
isomers. Interestingly, however, hydrolysis of the methyl ester yielded only the 
product containing the E double bond in pure form. The cause for this difference in 
reactivity of the two starting materials is unknown, but it was confirmed by NMR 
spectroscopy of both the isolated product and the recovered starting material. 
In order to diversify the set of pseudopeptides synthesised, we also wanted to use 
building blocks containing the triple- and Z double bond in the linker but lacking the 
terminal NH2 group. (Unpublished results) The copper-mediated coupling of methyl 
5-bromo-4-pentynoate 87 and Fmoc-protected iodoserine-O
t
Bu 86 seemed to run 
smoothly giving a crude product from which the desired compound could be easily 
separated. Disappointingly, NMR spectroscopic analysis of both crude and purified 
products showed that this reaction yields only traces of the desired product, thus 
making the reaction unfeasible as a tool for accessing the desired compound(s). 
With the required building blocks 84a, 84b, 85a, and 85b in hand we employed 
standard Fmoc chemistry to synthesise the pseudopeptides on solid phase using Rink 
amide AM resin resulting in products carrying a C-terminal amide instead of a 
carboxylic acid after cleavage from the resin. In this particular case, the peptide was 
attached to the resin from the side chain carboxylic group of Fmoc-Asp-OAll, 
corresponding to the Asn6-residue in the original peptide (5). This means that the 
synthesis of the peptide needs to be finished by the hydrolysis of the allyl ester of the 
Asp6/Asn6-residue, removal of the Fmoc-group and finally a head-to-tail cyclisation 
of the pseudopeptide (Scheme 12). This approach has been successful in previous 
syntheses of modified analogues of peptide B-2.
55
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Scheme 10 Synthesis of building blocks used for pseudopeptide analogues of the B-2 peptide. 
 
Scheme 11 Attempted synthesis of an alkyne linker lacking the terminal NH2 group 
As previously, the resulting pseudopeptides were purified by HPLC and their 
identity was verified by mass spectrometry. 
In order to further verify the exact structure of the pseudopeptides and more 
specifically the orientation of the double bond, an NMR study was undertaken. By 
using the same method as previously mentioned,
178,179,263
 we investigated the 
chemical shifts of the methine protons in the hydrocarbon linkers. This showed that 
the final pseudopeptide contained the E-isomer exclusively. 
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Scheme 12 Strategy used fot the solid-phase synthesis of pseudopeptides 79a-79d 
All four pseudopeptides stimulated the activity of KLK3 but the effects were 
weaker compared to original peptide 5 and slightly weaker compared to the earlier 
analogues with a linker consisting of aspartic acid and γ-amino butyric acid.55 The 
increase in enzymatic activity of KLK3 in the presence of pseudopeptides 79a and 
79b as compared to KLK3 alone were 161 and 247 %, respectively. Similarly, 
activities for pseudopeptides 79c and 79d were 150 and 167 %, respectively. 
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4 QUINOLONE-BASED SCAFFOLD 
PEPTIDOMIMETICS (PAPER IV) 
4.1 DESIGN OF A MIMETIC OF THE C-4 PEPTIDE 
When using a peptide as the starting point one alternative for improving the 
bioavailability is the development of a scaffold-based peptidomimetic, i.e. a small-
molecular weight compound which retains the biological effect by interacting with 
the same target as the parent peptide. Even though this approach to the development 
of peptidomimetics is quite difficult, it was chosen for taking the step from peptides 
to peptidomimetics in this project. 
One of the most important tasks of this approach is to identify the part or parts of 
the peptide that are required for the biological activity. This in turn requires 
knowledge of the bioactive conformation of the peptide. In an ideal case the 
bioactive conformation and binding site of the peptide would be determined 
experimentally by e.g. either NMR spectroscopy or X-ray diffraction experiments 
performed on the crystallised peptide-protein complex. If experimental data are not 
available, molecular modelling studies can instead be used to form an educated 
guess. 
Unfortunately, the amount of structural information available on KLK3 is limited 
and even the available information has some degree of uncertainty as the available 
crystal structures also contain antibodies and substrate molecules.
11,12
 What is 
however known is that KLK3 has an active site consisting of three residues (His57, 
Asp102 and Ser159) situated under a flexible loop-structure (the kallikrein 
loop).
9,10,54,56
 It has also been hypothesised that peptides and antibodies can bind to 
this loop “locking” it in an open conformation in order to make it easier for a 
substrate to reach the active site, thus stimulating the activity of KLK3.
54,56
 Based on 
this observation and NMR-studies of the C-4-peptide (4) a docking study was 
performed to determine the binding site of the peptide on the kallikrein loop and 
consequently also the interactions needed for binding the peptide to the enzyme.
10
 
As there is only a limited amount of data available on the binding interactions of 
the peptides stimulating KLK3 it is difficult to reliably design a peptidomimetic with 
a specific activity on KLK3. Instead, we chose a scaffold structure that contains 
enough possibilities for varying the substitution pattern to be considered a general 
scaffold for peptidomimetics. The simpler the protocol for synthesis of the scaffold 
and further substitution of it, the easier it will be to adapt the mimetic to different 
targets. 
Three scaffolds were considered for the mimetics in this project; chromone 89, 4-
quinolone 90 and 3,5-diketopiperazine 91. Even though these structures seem quite 
different they do share some of the critical properties, namely they are all fairly 
planar and rigid structures with possibilities for substitution in several positions. The 
main reason for selecting these scaffolds was the flexibility of allowed substitution 
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patterns combined with the previous use of the chromone and diketopiperazine 
scaffolds within the Luthman group at the University of Gothenburg.
226,265,266
 
 
 
Using a previously published homology model of KLK3,
10
 an energy minimised 
conformation of peptide 4 (C-4) was docked in the presumed binding site and we 
proceeded to study the interactions between the peptide and KLK3 to identify the 
amino acid side chains that are necessary for the biological activity of the peptide. 
An image of part of the peptide docked on KLK3 can be seen on the cover of this 
thesis. This study showed that His9, Trp11 and Thr12 in 4 seem to be responsible for 
the peptide’s interaction with KLK3. This is in agreement with the alanine-
replacement studies that showed that His9 and Trp11 are required for biological 
activity, the study also showed that replacing Thr12 together with Val2 causes a 
significant drop in the biological activity of the peptide.
267
 In order to design a 
peptidomimetic of 4, we were looking for a scaffold that could allow the important 
side chains to be placed in correct relative positions. Additionally, the scaffold 
should enable alternative substitution patterns if fine tuning of the peptidomimetic is 
needed. 
 
Figure 19 The structure of peptide 4 and the corresponding peptidomimetic 92 
A 1,2,8-trisubstituted 4-quinolone scaffold (92a) was found to fulfil both of these 
criteria. Based on the information gained from the docking study of peptide 4 and the 
preliminary evaluation of different scaffolds 92 was chosen as the structure for the 
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peptidomimetic. The generalised structure of the 4-quinolone based mimetic together 
with a superposition of the energy minimised structure of 92 and the peptide 
fragment in question (His9-Cys10-Trp11-Thr12 in C-4) are shown in Figure 20. In 
this structure the groups R
1
, R
2
, and R
8
 correspond to the side chains of the amino 
acid residues the compound it is intended to mimic. 
   
Figure 20 General structure of quinolone-based peptidomimetic 92a (right), an overlay of the 
energy minimised structure of 92 on the corresponding peptide fragment in C-4, i.e. 
His9-Cys10-Trp11-Thr12 (left). The hydrogen atoms are omitted for clarity. 
Even though compounds based on 4-quinolones have been used as drugs since the 
late 1960s, these compounds are mainly based on the 4-quinolone-3-carboxylic acid 
core 93 or the analogous 6-fluorinated core 94. These compounds have been 
extensively used as antimicrobials and broad-spectrum antibiotics,
268,269
 although 
concerns have been raised regarding their side effects and their susceptibility to 
antibiotic resistance.
270-272
 When considering the classification of the quinolone 
scaffold as a privileged structure
240,269,273
 and it also having been shown to have 
biological activity for several different targets
269
 it seems like an attractive scaffold 
for a peptidomimetic. 
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4.2 SYNTHESIS OF A PEPTIDOMIMETIC BASED ON 
THE 4-QUINOLONE SCAFFOLD  
One of the consequences of the success of the fluoroquinolones is that most synthetic 
protocols published in this field are aimed at 4-quinolone-3-carboxylic acids.
269
 It 
should also be noted that even though isolated examples of decarboxylation of 
quinolone carboxylic acids exist in the literature, even the decarboxylation of the 
simpler quinolones requires heating to 240-270 °C
274,275
 or alternatively refluxing in 
a high-boiling solvent such as diphenylether,
276
 making this approach less attractive 
for more complex compounds. 
Despite the interest in the 4-quinolone-3-carboxylic acids, several methods for 
the synthesis of other quinolones have also been published. Six of the more common 
routes are outlined in Scheme 13. These strategies have in common the use of an 
aniline as the starting material in a condensation reaction followed by a cyclisation to 
yield the final product. The exception to this is Camps quinoline synthesis presented 
as number 1 in the scheme. In this method an ortho-acylaminoacetophenone is 
transformed into a 4-quinolone in the presence of hydroxide ions.
277
 Routes 2 and 3 
utilise β-ketoesters to form the intermediate enaminoester through an acid-catalysed 
substitution on the aniline nitrogen followed by cyclisation in a high-boiling 
solvent.
278-283
 Routes 4 and 5 on the other hand use methoxy (MeO-) or methylthio 
(MeS-) substituted alkenes for the formation of the enaminoester by removal of the 
corresponding alcohol or thiol.
284-287
 A modification of this method uses trimethyl 
orthoformate to generate the methoxymethylene moiety in situ (not shown in 
Scheme 13).
287
 A modification of the two previous methods is outlined in route 6 in 
Scheme 13. Here, an aniline is reacted with acetylene dicarboxylate to afford the 
intermediate.
288-290
 This reaction has also been shown to be successful when using 
butynoic acid or esters to give 4-quinolones.
291,292
 
Even though much of the older literature concerning these syntheses report the 
product as being a 4-hydroxyquinoline it has later been shown that the keto-isomer 
(4-quinolone) dominates over the enol in the product. This is clear e.g. in NMR-
spectroscopy where only a minute portion of the enol tautomer is visible at room 
temperature. If the 4-hydroxyquinoline or derivatives thereof are needed, one 
possible strategy for synthesis is to use phosphorous oxychloride (POCl3) to get the 
4-chloroquinoline which can further be reacted with benzyl alcohol to get the 
corresponding benzyl ether.
281
 
Other methods for the synthesis of 4-quinolones have been published, but as 
these are even more limited in the scope of substitution on the final product they will 
not be covered here.
293-299
 These limitations are caused both by the requirement of 
synthesising complex starting materials
293,294,299
 and the limitations to the diversity 
of the product caused either by the mechanism of the reaction or the starting 
materials used.
295-297 
When reviewing the literature on the synthesis of 4-quinolones it becomes obvious 
that even though most types of substituents can be found, the different methods all 
have limitations to their compatibility with different substitution patterns. For 
example route 5, using Meldrums acid, gives the possibility to use anilines substi- 
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Scheme 13 Retrosynthetic analysis of different routes found in the literature for the synthesis of 
4-quinolones 
tuted in many different ways but the variations possible in the R
2
-position are 
extremely limited.
285-287,294,300,301
 This can partially be worked around by modifying 
the R
2
 side-chain after the synthesis of the ring system but this is also limited to 
substituents linked to the ring by a heteroatom (O, N or S).
286,294,300
 Route 4 in the 
scheme also suffers from this limitation as it is not possible to introduce an R
2
-
substituent using this method and it also results in an ester group in the 3-position.
284
 
The synthetic routes starting from a β-ketoester and an aniline offer excellent 
possibilities for the synthesis of a variety of 4-quinolones as a large number of 
different β-ketoesters can be synthesised from their corresponding acids using simple 
procedures.
302,303
 The problem in this context is the limited compatibility towards 
substitution especially in the 8-position of the final product (the ortho-position 
relative to the aniline nitrogen). Even though examples have been published of 5-, 6- 
or 7-halo substituted quinolones synthesised using this method,
275,282,283
 compounds 
bearing a halogen substituent in the 8-position are rare. In fact, only one example can 
be found reporting the synthesis of an 8-bromo substituted 4-quinolone starting from 
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a β-ketoester.304 Additionally, there has also been only limited work done on the 
synthesis of e.g. 6,8-dihalosubstituted quinolones bearing two different halogen 
substituents which would offer the possibility of attaching two different side chains 
to the quinolone core regioselectively. Examples do exist of 5,7-dichloro-4-
quinolone
283
, 6,8-dibromo-4-quinolone
305
 and 6,8-difluoro-4-quinolone.
306
 It should 
be possible to further derivatise these compounds on both halogen positions but as it 
is unlikely that it will be possible to selectively substitute only one of the halogens 
the usefulness of these compounds is somewhat limited. It is also possible to 
synthesise a 6-amino-8-methoxy-4-quinolone
307
 in which both of the substituents on 
the aromatic ring can be reacted further, although there are significantly more 
possibilities for the substitution of halogens than of substituents of other 
heteroatoms, such as O, N and/or S. 
In order to make the series of compounds as diverse as possible, 4-quinolones 
with several different R
2
-side chains were synthesised. The side chains were chosen 
to represent the different types of side chains found in the natural amino acids. The 
chosen alternatives were alkyl (butyl and pentyl), aromatic (benzyl), amino (4-
aminobutyl), carboxylic acid (methyl 4-pentenoate) and hydroxyl ((R)-2-
hydroxypropyl, 3-hydroxypropyl and 4-hydroxybutyl). The different chain lengths in 
the substituents also show if this affects the reactivity. 
The first step in the synthesis of the quinolones was the preparation of β-
ketoesters 97a-j containing the side chain which will end up in the 2-position of the 
final 4-quinolone. They were obtained in good yields by reacting the corresponding 
carboxylic acids 95a-j and monomethyl potassium malonate 96 with N,N’-
carbonyldiimidazole (CDI) in anhydrous THF at room temperature.
302
 Protected (R)-
3-hydroxybutanoic acids were prepared from methyl (R)-3-hydroxybutyrate via 
benzyl
308
 or TBDMS
309
 protection of the alcohol and subsequent hydrolysis of the 
ester.
310
 N-Phthalimide-protected 5-aminovaleric acid 95e was prepared by 
modifying a known procedure.
311
 Pivalic esters 95f and 95g were prepared from 
pivaloyl chloride and methyl 4-hydroxybutyrate, and methyl 5-hydroxypentanoate, 
respectively, the methyl esters were subsequently hydrolysed using lithium 
hydroxide in aqueous methanol. Methyl 4-hydroxybutyrate and methyl 5-
hydroxypentanoate were prepared from γ-butyrolactone312 and δ-valerolactone,313 
respectively, according to known procedures. 
4-Quinolones 100-113 were synthesised employing the Conrad-Limpach 
reaction. The β-ketoesters were stirred together with the corresponding anilines 98a-
c under argon at 50 °C for 48 h to afford the intermediate enaminoesters 99a-e. After 
removal of excess aniline and p-toluenesulphonic acid (PTSA) the cyclisation was 
achieved by heating the enaminoesters to 250 °C in diphenyl ether for 45 min using 
microwave heating. The quinolone products 100-113 were finally isolated by 
crystallisation from hexane. 
The yields for successful reactions run using the developed conditions are 
reported in Table 3. The results indicate that several substituents with varying chain 
lengths could be introduced in the 2-position. A major exception was the compounds 
with substituents with a protected hydroxyl group in the 2-position. Synthesis of 
these using the same method as the other 4-quinolones was unsuccessful and  
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Scheme 14 Synthesis of 4-quinolone scaffolds. Reagents and conditions: i) CDI, MgCl2, THF, 
20 °C, 16 h. ii) 98a-c, PTSA, neat, 50 °C, 48 h. iii) Cyclohexane, reflux, 30 min. iv) 
Diphenyl ether, MW, 250 °C, 45 min. Piv= pivaloyl (-OC(CH3)3) 
attempts to use different conditions did not improve the situation (Scheme 15). A 
number of different protecting groups (pivaloyl ester, benzyl ether and TBDMS), 
chain lengths and synthetic methods were attempted. However, the hydroxyl group 
can also be introduced via an ester-bearing side chain in the 2-position (as in 110-
112) which it should be possible to subsequently reduce to the corresponding alcohol 
using a previously reported method.
314
 
When examining the yields of the successful reactions, it is obvious that 
reactions resulting in a product with bromine in the 8-position give low yields (14-
31%), whereas reactions resulting in a product with hydrogen in the 8-position give 
better yields (34-55%). This is a clear trend in the successful reactions. Interestingly, 
whether or not the product has a halogen atom (chlorine or bromine) in the 6-
position does not seem to affect the yield of the reaction. 
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Table 3. Successfully synthesised quinolone scaffolds 
Compound R
2
 R
6
 R
8
 Yield %
a 
100 
 
Cl Br 31 
101 Cl H 42 
102 H Br 14 
103 Br H 39 
104 
 
H Br 29 
105 Cl Br 25 
106 Cl H 34 
107 
 
H Br 25 
108 Cl Br 24 
109 Cl H 55 
110 
 
H Br 18 
111 Cl Br 26 
112 Cl H 39 
113 
 
H Br 26 
a
Yields calculated over two steps from 97a-e 
 
Scheme 15 Syntheses of 4-quinolones with an oxygen-bearing subsituent in the 2-position. i) 
0.1 eq. PTSA, neat, 50 °C 2-16 days. ii) catalytic amount of silica gel, neat, 50°C, 2 
days. iii) cat. conc. HCl, neat, 50 °C, 2 days. iv) PTSA, AcOH, 50 °C, 2 says. v) 
EtOH, catalytic AcOH, reflux 2 days. vi) EtOH, catalytic AcOH, CaSO4, 50 °C, 2 
days. vii) Cyclohexane, reflux, 30 min. viii) Diphenyl ether, MW, 250 °C, 45 min. 
Piv=pivaloyl 
Alkylation of the nitrogen in the pyridinone-ring (the 1-position) of the 4-quinolone 
is one of the key features that makes it an attractive alternative for a peptidomimetic 
scaffold. The most common way of doing this substitution is to use a suitable alkyl 
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halide in the presence of a base. This has been shown to be successful using even 
mild conditions; K2CO3 is often used for the reaction.
315
 If an N-methylation is to be 
done the substitution is usually performed as described above, using methyl iodide 
and a suitable base.
316
 The use of diazomethane has also been reported although the 
N-methylated compound was only the product of a side reaction in this case.
317
 If the 
required halide is not easily available another alternative for the substitution is to use 
an alcohol in a Mitsunobu reaction. One example of a Mitsunobu reaction on a 4-
quinolone has been published
318
 but this is clearly an approach that has not been 
thoroughly investigated. When looking at the patent literature, a few examples of 
similar Mitsunobu reactions can be found where the alcohol has been activated to a 
mesylate.
319
 
The final step in the decoration of the quinolone scaffold is the introduction of 
substituents on the aromatic ring. If the aromatic ring bears e.g. a bromo substituent, 
this can be done by a palladium-mediated Heck-coupling as has been shown for 6-
bromo-4-quinolone.
320
 When using the chromone scaffold, which is similar to the 4-
quinolone, the Heck-reaction has been shown to be selective for an 8-Br-substituent 
also when a 6-Cl-substituent is present on the same ring.
265
 
Our initial strategy for introduction of substituents in the 4-quinolones was to 
first substitute the 1-position followed by a Pd-mediated Heck reaction on the 
brominated 8-position to obtain the final compound. Initially, attempts were also 
made to alkylate the nitrogen atom in the 1-position using an alkyl bromide (114 or 
115) and a base, but unfortunately none of the conditions tried for this reaction 
yielded the desired product. 
The DIAD or DEAD-mediated Mitsunobu reaction was chosen as a second 
alternative for this substitution and did produce the desired product although 
unfortunately as an inseparable mixture of the product and amine byproducts 
produced from DIAD or DEAD in the reaction. Based on NMR spectroscopic 
analysis of the product mixture the yield of the reaction was estimated to approx. 40 
%. Performing the Heck reaction on the impure product from the Mitsunobu reaction 
did not give any of the desired product. Whether this is caused by the impurities or 
some other reason was not investigated.  
 
Scheme 16 Reactions attempted for substitution of 4-quinolone 107. Reagents and conditions: 
i) NaH or Cs2CO3, DMF or THF, 25 or 100 °C, 4 – 16 h. ii) DIAD or DEAD, PPh3, 
chloroform, reflux, 16 h. 
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These problems required a change in strategy. The substituent in the 8-position of 
the quinolone was successfully introduced by a Pd(0)-mediated Heck-coupling that 
substitutes the bromide present on the aromatic ring. The reaction was performed in 
benzene using tris(dibenzylideneacetone)dipalladium(0) (Pd2(dba)3) and tri-tert-
butylphosphonium tetrafluoroborate ([(t-Bu)3PH]BF4) with microwave heating. 
Performing the reaction on the 6-chloro-8-bromo-substituted quinolone 111, we 
were also able to show selectivity of the bromide over the chloride in the Heck-
reaction. 
 
Scheme 17 Heck reactions used for the substitution of the 2-position of quinolone scaffolds 107, 
110, and 111. Reagents and conditions: i) Pd2(dba)3, [(t-Bu)3PH]BF4, benzene, 160 
°C, 30 min, MW. 
Substitution of the nitrogen atom in the 1-position of the final 4-quinolone was 
accomplished with an alkyl bromide under basic conditions (Scheme 18, Table 4). 
This reaction also simultaneously hydrolysed the methyl ester in compound 117a to 
yield 118a. Attempts to perform the same substitution by a DIAD-mediated 
Mitsunobu reaction failed to produce any product, probably due to the sterically 
crowded reaction site in combination with the bulky nature of the intermediate 
formed in this type of reaction. 
 
Scheme 18 Alkylation of intermediates 117a and 117b. The structures of the compounds are 
presented in Table 4. Reagents and conditions: i) R
1
Br, Cs2CO3, DMF, 100 °C, 16 
h. 
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Table 4. 1-Alkylated 4-quinolones 
Starting 
Material 
Product R1 R2 Yield 
117a 118a 
 
-(CH2)4CO2H
a 
64 
117b 118b -CH2Ph 50 
117b 118c -CH2Ph -CH2Ph 38 
117b 118d -(CH2)2Ph -CH2Ph 54 
a
R
2
 refers only to 118a. 
 
The final product was achieved by removal of the trityl groups from the imidazoles. 
This was done using 20 % TFA in DCM at room temperature in a yield of 92 %. 
 
Scheme 19 Deprotection of 118a to yield final product 119. Reagents and conditions: i) 20 % 
TFA in DCM, 90 min, room temperature. 
The ability of compound 119 to stimulate the proteolytic activity of KLK3 was 
determined in an assay using a chromogenic substrate.
54-56
 Unfortunately, the 
compound showed no KLK3-stimulating effect.  
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5 CONCLUSIONS AND FUTURE 
PROSPECTS 
The work presented in this thesis covers several years of work involving a large 
number of people. Even though there have been many successes, many things have 
also been unsuccessful and/or still remain to be done. This chapter aims to 
summarise what has been learned from the work and also add some considerations as 
to how the work could be continued in the future. 
5.1 REPLACING DISULPHIDE BRIDGES IN PEPTIDES 
Much of the work discussed has been aimed at the replacement of disulphide bridges 
in biologically active peptides in such a way that the pseudopeptides retain the 
biological activity of the parent peptide. The different building blocks presented in 
Chapter 3.1 represent interesting possibilities for replacing disulphide bridges in 
peptides. The four different general structures (31, 32a, 32b and 33) allow for the 
investigation of whether the sulphur atoms in the bridge are essential for the 
biological activity, they also represent different conformations of the bridge.  
The tolerance for different types of substrates for both the CM and copper-
mediated coupling reactions was further investigated in connection to the work on 
pseudopeptides based on the B-2 peptide (5) as it has been determined that the 
terminal NH2-group of said peptide is not necessary for biological activity. In order 
to further investigate this, it was decided to synthesise a set of pseudopeptides using 
two of the previously synthesised building blocks and analogues lacking the terminal 
amine. The synthesis of the building blocks required for these peptides once again 
brought with it some surprises concerning the reactivities of different substrates in 
these reactions. 
The conclusion from this is that the reactions discussed are apparently quite 
sensitive to both the structure of the starting materials involved and possibly also the 
reaction conditions. The exact cause of this observation remains unclear based on the 
number of experiments performed within this project. It is fully possible that the 
problems with low yields and mixtures of products could be solved just by 
optimising or changing the reaction conditions. Due to time constraints this was, 
however, deemed to be outside the scope of this project and not investigated further. 
As was discussed in some detail in Paper II (Chapter 3.1.2 of this thesis), the 
synthesised building blocks were originally intended to be used in in the synthesis of 
a pseudopeptide analogue of the C4-peptide (4), unfortunately with no success so 
far. As our original method for this synthesis using the building blocks directly in 
SPPS was unsuccessful due to problems with the removal of protecting groups from 
intermediate 66, we decided to first synthesise the smaller ring 70 of peptide 4 and 
attach this to the peptide chain as a building block in SPPS. Even though the 
synthesis of the ring itself was completed successfully, the selective hydrolysis of the 
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methyl ester proved to be a significant obstacle to this approach. The use of 
trimethyltin hydroxide has been useful for selective ester hydrolysis in many other 
applications, but in this case it seemed to mainly cleave the Fmoc from the peptide. 
The methods used for this reaction included both thermal and microwave heating for 
various lengths of time as well as changing the solvent. 
Despite the initial failures in the synthesis of the pseudopeptide analogues of 4 it 
was possible to synthesise these compounds using the RCM reaction for closing the 
smaller ring of the partially synthesised peptide. In this case the conditions found in 
the literature were not initially successful, but systematic modification of the 
conditions did eventually yield an efficient method for the synthesis of the 
pseudopeptides in Paper II.  
Even though the results from these syntheses and the biological evaluation of the 
pseudopeptides were extremely pleasing, the peptides were still not as potent as the 
peptides containing the native disulphide bridge. As has already been noted, the 
structure most likely to be able to mimic the conformation of the parent peptide is 
the one containing the linker with a Z double bond or the fully saturated chain. As 
the attempts to use the orthogonally protected building blocks in the synthesis of 
pseudopeptides in the place of an internal disulphide bridge had so far proved 
unsuccessful, the obvious method for obtaining these compounds would be the 
reduction of the double bond in the finished pseudopeptide. 
The lack of success in reducing the internal double bonds in pseudopeptides 76-
78 inevitably meant that a method for using the orthogonally protected building 
blocks is required to access pseudopeptides containing the various bridge-mimetics 
in pure form. This, of course, meant that the work on deprotection of intermediate 66 
had to be restarted, the strategy for this is outlined in Scheme 20. 
 
Scheme 20 Proposed route for the synthesis of C-4 analogues using an orthogonally protected 
building block. Reactions: i) Hydrolysis of methyl ester. Ii) Removal of Fmoc group. 
Iii) Peptide coupling. Iv) Removal of phthalimide group. 
Assuming that the problems concerning the deprotection of intermediate 66 can be 
solved and the synthesis of the pseudopeptide finished, this would lead to two 
significant advances in the investigation of the pseudopeptides of the C-4 peptide 
(4). Firstly, it would make it possible to investigate what effect the different linkers 
replacing the disulphide bridge have on the biological activity of the peptide. 
Secondly, it would also enable the use of the RCM-method for replacing the terminal 
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disulphide bridge in peptide 4 simultaneously with the internal one. In addition to 
giving some more information about how modifications of the peptide affect its 
biological activity, replacing the terminal disulphide could also have an effect on the 
stability of the peptide in plasma as the terminal disulphide bridge is likely to be 
more susceptible to reduction than the internal one. As has been proven with 
pseudopeptides based on 5, removing the terminal NH2-group from a peptide can 
also increase the stability.
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 Using a method analogous to that used to synthesise 
building block 84b it should be possible to introduce this type of structure in these 
pseudopeptides as well. Even if the RCM-reaction turns out to produce a mixture of 
the E and Z double bonds in this case as well, they should be separable by 
chromatographic methods and reducible using Pd/C in a hydrogen atmosphere 
according to what has been seen with other peptides containing hydrocarbon 
replacements for terminal disulphides. 
5.2 QUINOLONE-BASED PEPTIDOMIMETICS THAT 
MODULATE THE ACTIVITY OF KLK3 
The motivation for the study of the chemistry of the 4-quinolones lies in the original 
goal of the project to create a small molecular weight compound with a biological 
activity like that of the peptides and pseudopeptides discussed in this work. The 
starting point for the work in designing a compound with this activity was to study 
the (partly unpublished) work that has been done on modelling the interactions 
between KLK3 and the C-4 peptide (4). In this work, the C-4 peptide has been 
docked onto the kallikrein loop of KLK3 in order to identify both a possible binding 
site for the peptide and also what interactions are required for binding. 
By closely studying the structure of the peptide docked on a homology model of 
the protein it is possible to identify His9, Trp11 and Thr12 as the residues that 
interact with KLK3 via hydrogen bonding. Especially interesting is the observation 
that the imidazole ring of His9 fits neatly into a cavity in the kallikrein loop directly 
above the active site of the enzyme. Figure 21 shows the peptide docked on the 
protein, for clarity the parts of that are not directly participating in the interaction 
have been omitted. 
Based on the information from this study, a few different scaffolds were 
investigated for their ability to mimic the structure of the peptide backbone. When 
the side chains corresponding to the residues mentioned previously had been 
attached to the 4-quinolone scaffold using spacers of suitable length, the compound 
energy minimised and subjected to a conformational search, it showed good 
agreement with the His9-Thr12 fragment of the peptide as illustrated in Figure 20 on 
page 45. 
One surprising and unfortunate observation that was made in the course of the 
synthesis of the 4-quinolones was the difference in reactivities of the β-ketoesters 
depending on the type of oxygen-bearing substituent (Scheme 15). The exact cause 
for this problem has not been investigated more closely, although NMR analyses and 
MS analysis of intermediate 99 from these reactions did indicate that for some 
 57 
reason the product formed in the first reaction is not the desired enaminoester. From 
the analyses that have been performed it is not immediately apparent what has 
actually happened in the reaction. 
 
Figure 21 The C-4 peptide docked on the kallikrein loop of KLK3. Amino acid residues in the 
peptide not directly participating in the interaction with KLK3 have been removed for 
clarity. 
As a consequence of these problems, it is clearly necessary to find a different 
strategy for the synthesis of the quinolones with a hydroxyl-bearing substituent in 
the 2-position. One possibility is to first synthesise the 4-quinolone with an 
unsaturated R
2
 side chain, then add the hydroxyl at a later stage through a suitable 
reaction to complete the synthesis as outlined in Scheme 21. 
 
Scheme 21 Proposed synthesis of a hydroxyl-bearing 4-quinolone using the Conrad-Limpach 
reaction. 
There are also two interesting alternative routes found in the literature that utilise 
modified Camps’ cyclisations to access a quinolone with an unsaturated side chain in 
the 2-position.
277,321
 Of these, the procedure outline in Scheme 22 uses commercially 
available o-aminoacetophenone 120 and crotonic acid 121 to give a 2:3 mixture of 
the two quinolones in two steps.
321
 Whether or not it is possible to separate the two 
compounds is not discussed in the paper. 
Conclusions and future prospects 
58 
 
Scheme 22 Use of a modified Camps’ quinoline synthesis to access 4-quinolones with a 
substituent in the 2-position containing an alkene moiety.
321
 Materials and methods: 
i) PyBroP (1.1 eq.), TEA (1.1 eq.), DCM (0.1 M), r.t., 16 h. ii) TEA (3 eq.), TMSOTf 
(6 eq.), DCE (0.05 M), reflux. 
5.3 SIRT2 INHIBITORY ACTIVITY OF 4-QUINOLONE 
BASED COMPOUNDS 
Even though none of the quinolones intended to be tested for stimulation of KLK3 
have so far been successfully synthesised and tested, some of the compounds have 
instead been tested as inhibitors of sirtuin 2 (SIRT2), a family of NAD
-
 dependent 
histone deacetylases. The sirtuins have become highly interesting targets for drug 
discovery as they are involved in a number of important cellular processes and have 
been implicated in certain disease states related to aging and consequently to 
neurodegenerative diseases such as Alzheimer’s, Parkinson’s, or Huntington’s.322-325 
One highly potent and selective inhibitor of SIRT2, 8-bromo-6-chloro-2-
pentylchromone 122 (82 % inhibition at 200 µM, IC50 = 5.5 µM) and SAR-studies 
indicate that large, electron withdrawing groups in the 6- and 8-positions are 
favoured.
326
 As some of the synthesised 4-quinolones are also 8-bromo-6-chloro-
substituted and structurally quite close to chromone 122, they were also tested for 
SIRT2-inhibition, the results are shown in Table 5. 
Table 5. SIRT2 inhibition of 4-quinolone compounds 
Compound R
2 
Inh. %, 200 µM 
(± SD) 
122  82 (0.4) 
100 -(CH2)3CH3 47 (0.9) 
105 -(CH2)4CH3 26 (1.4) 
108 -CH2Ph 58 (2.1) 
111 -(CH2)4CO2Me 53 (1.1) 
 
Even though none of the tested 4-quinolones are exceptionally potent, they are quite 
good for being a first, un-optimised set of compounds. One of the obvious 
differences between the quinolone and chromone is the NH-group which makes the 
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quinolone more hydrophilic than the chromone which can be problematic as the 
inhibitors have been proposed to bind in a hydrophobic pocket on SIRT2.  
With some additional compounds it should be possible to improve the activity at 
least to some degree making this an interesting application for the 4-quinolone 
scaffold. Even as such these compounds serve as proof that 4-quinolone is indeed a 
privileged structure and also proves it is a good bioisostere of the chromone ring 
system. This clearly underlines one of the major advantages with working with 
privileged structures, the simple transition from one target to another one. 
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